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ABSTRACT 
ADAM DAVID FRIEDMAN: The Selection of Highly Stable Aptamers Selected from a 2’-
fully modified fGmH RNA Library  
(Under the direction of Rihe Liu) 
 
When developed as tools for applications within biological systems, RNA aptamers 
immediately face numerous obstacles, in particular nuclease degradation and post-selection 
2’ modification. This study aimed to develop a novel class of highly stable, 2’-fully modified 
RNA aptamers directly selectable from a fGmH RNA library with improved nuclease 
stability. The facile transcription of a fGmH (2’-F-dG, 2’-OMe-dA/dC/dU) RNA library was 
performed, from which aptamers were directly selected that bind Staphylococcus aureus 
Protein A (SpA). The superior nuclease and serum stability of these fGmH aptamers was 
demonstrated in comparison to 2’-partially modified RNA variants. Characterizations of 
fGmH RNA aptamers binding to purified SpA and to endogenous SpA present on the surface 
of S. aureus cells demonstrated fGmH RNA aptamer selectivity and stability. Significantly, 
fGmH RNA aptamers were able to functionalize, stabilize, and specifically deliver 
aggregation-prone silver nanoparticles (AgNPs) to S. aureus with SpA-dependent 
antimicrobial effects. Attempted selection of fGmH RNA aptamers against other targets, 
namely the PD-1 immune checkpoint, led to the selection of a single non-binding sequence 
during the selection against PD-1, as well as several non-binding sequence motif groups 
during the selection against PD-L1. Overall, this dissertation demonstrates the selection and 
deployment of Protein A binding fGmH RNA aptamers against S. aureus, discusses 
	   iv	  
hypotheses and results aimed at explaining the selection of PD-1 and PD-L1 non-binding 
sequences, and describes a novel aptamer class with considerable potential to improve the in 
vivo applicability of nucleic acid-based affinity molecules. 
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CHAPTER 1 
APTAMERS: INNOVATIONS IN NUCLEASE STABILITY, MACROMOLECULAR 
TARGETING LIGANDS, AND AN EXPLANATION OF THE UNMET NEEDS 
TARGETED BY THIS STUDY 
 
1.1  Introduction: Aim of the Dissertation 
The aim of this dissertation is to investigate a novel aptamer class with considerable 
potential to improve the in vivo applicability of nucleic acid-based affinity molecules. In the 
process of performing the first proof-of-concept fGmH (RNA composed of 2’-F-dG and 2’-
O-methyl-dC/dA/dU) RNA aptamer selection, fGmH RNA stability against serum and a 
panel of individual nucleases was assessed, and a selected fGmH RNA aptamer, fmA12, was 
used as a targeting ligand for the specific delivery of antimicrobial silver nanoparticles 
(AgNPs) to Staphylococcus aureus. This chapter will provide an overview of nuclease 
stability issues of various nucleic acids, the use of aptamers as targeting ligands as compared 
to other macromolecules, and a description of the research approach pursued during the 
course of this dissertation.  
1.2 Aptamers and Innovations in Nuclease Stability 
Developed in the 1990s by the Szostak, Gold, and Joyce groups through an in vitro 
selection process, aptamers are short single-stranded nucleic acids (RNA or single stranded 
deoxyribonucleic acid (ssDNA)) capable of diverse structures with the potential for binding 
many biochemical and non-biochemical targets, from small molecules to large proteins (1-4). 
This expansive potential binding ability is harnessed by iterative selection from a nucleic 
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acid library, where every sequence within the library contains 20 to 50 random residues, 
which determines the diversity of the potential aptamer pool. Although the theoretical 
diversity is an astronomical figure, the realistic diversity that can be achieved experimentally 
is typically in the range of 1 × 1013 to 1 × 1015 unique sequences. The high sequence and 
conformational diversity of the initial nucleic acid pools ensures a high probability of 
discovering aptamers that bind to numerous targets of interest (5, 6). Aptamer selection, 
oftentimes called the Systematic Evolution of Ligands by EXponential enrichment (SELEX), 
involves iterative rounds of binding to a target of interest, partitioning between binding 
versus non-binding sequences, and amplification of the enriched target binding aptamers for 
the next round of selection (Fig. 1.1).	   
Figure 1.1. Scheme for aptamer selection via SELEX. 
 In general, RNAs represent most of the existing aptamers because unlike ssDNA, 
RNA is more inclined to fold into stable and complicated secondary and tertiary structures 
for numerous biological functions (6). However, nucleases, which are highly abundant in the 
biological fluids of almost any organism, rapidly degrade aptamers derived from natural 
nucleic acids. Natural RNAs are rapidly and extensively degraded, whereas natural DNAs, 
although relatively more stable than RNAs, are also quickly degraded by deoxyribonucleases 
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and many nonspecific nucleases, yielding half-lives in the range of 30 to 60 minutes (5). This 
section will discuss relevant advances in nucleic acid stabilization, use of nuclease-stabilized 
naïve aptamer libraries in SELEX, and unmet needs. 
1.2.1 RNA Modification 
RNA with 2’ modifications exhibits increased resistance to many nucleases by 
reducing hydrolysis of the phosphodiester backbone (7). In vitro, natural RNA exhibits half-
lives of seconds to a few minutes in various biological fluids including human serum, 
whereas RNAs partially modified at the 2’ position have extended half-lives of 5 to 15 hours 
(5, 7, 8). Before the advent of aptamers, the nuclease stabilizing effect of 2’-fluoro (2’-F) and 
2’-amino modifications on RNA was well-known, and this knowledge was applied to 
hammerhead ribozymes (i.e. RNA enzymes) after their discovery by Cech and coworkers (9-
11). Without disrupting catalytic activity, Eckstein and coworkers replaced a subset of the 
hammerhead ribozyme’s nucleotides with 2’-F or 2’-amino equivalents, thus increasing 
ribozyme nuclease stability without disrupting catalytic activity (12). Yang and coworkers 
continued this work using 2’-O-methyl (2’-OMe) modifications on a subset of nucleotides, 
and were able to both maintain catalytic activity and increase nuclease resistance 1000-fold 
(13). Similarly, Paolella and coworkers achieved similar success using 2’-O-allyl 
modifications, which only reduced catalytic activity 5-fold but increased survival in bovine 
serum after 2 hours to 30% (14). By using various combinations of modified ribouridines 
(i.e. 2’-OMe, 2’-F, 2’-amino, 2’-allyl, 3’-3’ inverted T, 2’ arabinofluoro, 2’-methylene, and 
2’-difluoromethylene), Beigelman and coworkers were able to maintain catalytic activity and 
increase ribozyme T½ to greater than 260 hours (15). 
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In addition to conferring nuclease resistance, 2’-OMe and 2’-F modifications stabilize 
base pairing. Residues bearing a 2’-OMe prefer a C3’-endo pucker due to steric repulsion 
with the 2-carbonyl, the 2’-OMe, and 3’-phosphate (16, 17). Due to the high 
electronegativity of fluorine, nucleosides bearing a 2’-F moiety also adopt an RNA-type C3’-
endo sugar conformation, but this is partially due to the 2’-F exerting a gauche effect on the 
sugar (18). RNA residues bearing a 2’-F moiety potently increase the hybridization stability 
between oligonucleotides and RNA at approximately 1.8 °C per residue (a possible result of 
enthalphy effects and enhanced stacking interactions resulting from the high electronegativity 
of fluorine) compared to about 1.3 °C and 1.0 °C per residue when 2’-OMe and 2’-OH 
residues are used, respectively (19, 20). 
1.2.2 Incorporating Nuclease Stability into SELEX 
2’-OMe and 2’-F modifications on pyrimidines and some purines have been 
commonly used for stabilizing aptamers (5, 7, 8, 21, 22). When aptamers intended for an in 
vivo application are first selected from natural or 2’-partially modified RNA libraries, further 
stabilization of these aptamers by installation of additional 2’-modified residues is desirable 
yet challenging. 2’-hydroxyls can participate in aptamer:target interactions or in the structural 
folding of functional aptamers via hydrogen bonding. Therefore, post-selection replacement 
of residues bearing 2’-hydroxyls with 2’-modified variants carries a high risk of disrupting 
the structure and target affinity of the aptamer.  
Direct selection of aptamers from 2’-partially modified (2’-F-dC/dU, 2’-OH-rG/rA: 
fYrR) RNA libraries partially addresses this problem. For example, anti-VEGF aptamer 
NX1838, later developed into the only FDA-approved aptamer drug Macugen, was selected 
from an initial fYrR RNA library. Post-selection, every 2’-hydroxyl (2’-OH) purine was 
	   5	  
replaced with a 2’-OMe purine analog one at a time. Each NX1838 variant bearing a new 
single 2’-OMe purine analog was chemically synthesized and tested for target binding. This 
systematic testing found that all but two purines bearing 2’-hydroxyls could be replaced with 
2’-OMe purines and maintain target-binding affinity and inhibitory activity against 
VEGF165-mediated signaling (23, 24). Though ultimately successful, the chemical synthesis 
and affinity testing performed via this strategy was exceptionally tedious, time-consuming, 
and still limited in addressing the problem.  
1.2.3 Unmet Needs 
Direct selection of 2’-fully modified aptamers from 2’-fully modified RNA libraries 
would provide a highly simplified approach for the development of aptamers intended for in 
vivo applications. However, existing T7 RNA polymerase mutants do not efficiently generate 
2’-fully modified RNAs, making direct selection of such libraries difficult (8, 21, 25, 26). 
Work by Sousa and coworkers identified two T7 RNA polymerase mutants (Y639F and 
Sousa Variant Y639F/H784A) that allow for the efficient accommodation of 2’-F-pyrimidine 
ribonucleotides as substrates during in vitro transcription (27, 28). Keefe and coworkers 
identified a reaction condition that allowed the Sousa Variant to incorporate significant 
amounts of 2’-OMe-dGTP into transcripts in the presence of 5.7% 2’-OH-rGTP, resulting in 
RNAs that were mostly fully modified for in vitro selection (8, 25). To overcome the concern 
of 2’-OH-rGTP incorporation during transcription, they supplemented the transcribed initial 
library in the first round of selection with a library chemically synthesized with only 2’-OMe 
ribonucleotides. Whereas this strategy has a reasonable chance to work, the heterogeneous 
2’-OMe-dG/2’-OH-rG nature of this system makes it difficult to rule out the possibility of 2’-
OH-rG involvement in the selected aptamer structures. Because of this, time-consuming 
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post-selection functional testing using chemically synthesized 2’-OMe modified aptamer 
variants should be performed. In addition, it is unknown whether this selection would have 
been successful if the chemically-synthesized, all 2’-OMe-modified library, with a quality 
typically much lower than that of enzymatic synthesis, had not been included in the overall 
first round.  
1.3 Macromolecular Targeting Ligands 
 The use of aptamers as targeting ligands both in vitro and in vivo has been pursued in 
the literature with vigor since shortly after their development in 1990 by Ellington and 
Szostak. As macromolecular targeting ligands, aptamers and polypeptide-based targeting 
ligands each have unique features that can make the former advantageous over the latter, and 
vice versa. The attractiveness of aptamers as biopolymers for “smart” targeting, particularly 
for in vivo applications, derives from multiple properties that allow aptamers to outperform 
affinity ligands from other classes. Aptamers are typically non-toxic, non-immunogenic, 
functionalizable, and chemically synthesizable with little batch variation (29). Diminutive 
compared to most biologics and able to form compact structures, aptamers can often bind 
epitopes, clefts, and enzymatic active sites that are relatively inaccessible to antibodies (30). 
Indeed, the selection of aptamers with target-binding affinities higher than natural ligands, 
typically in the low nanomolar to picomolar range, is routine (24, 31, 32). This is due to the 
imposition of specific evolutionary pressures on a simplified experimental system by the 
researcher, instead of natural selection on complex biological systems. Affinities of selected 
aptamers can be improved further via well-established procedures that reintroduce diversity 
to the selected aptamer pool, such as via additional selection of aptamer pools generated via 
doped synthesis of a nucleic acid sequence with demonstrable affinity for the target (33). 
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Importantly, it is possible to synthesize aptamers with a specific functional moiety, such as a 
carboxylate, amino, sulfhydryl, or aldehyde, at only one end of the nucleic acid aptamer. This 
ensures, and greatly facilitates, site-specific conjugation with a wide variety of biomaterials 
and prevents the formation of heterogeneous mixtures. 
As a prelude to Chapter 2, wherein the deployment of S. aureus Protein A-binding 
aptamer fmA12 as a silver nanoparticle targeting ligand will be described, this section will 
discuss and compare the uses of aptamers and polypeptides as targeting ligands. 
1.3.1 Aptamers 
Aptamers are well-suited to serving as targeting ligands. It is possible to synthesize 
aptamers with a specific functional moiety, such as a carboxylate, amino, sulfhydryl or 
aldehyde, at only one end of the nucleic acid aptamer. This ensures and greatly facilitates 
site-specific conjugation and prevents the formation of heterogeneous mixtures. Aptamers 
are typically non-immunogenic (34). Many other attributes make aptamers attractive for 
nanoparticle targeting, such as being non-toxic (34-36) and modifiable for stability in 
circulation (37). They can be selected in vitro and in vivo, and be repeatedly and reversibly 
denatured. Moreover, as aptamers are not dependent on animals or their immune responses, 
aptamers can be selected against weakly immunogenic targets and toxins. The ability to 
chemically synthesize aptamers infers little batch variation (29). They are much smaller than 
antibodies and can form compact structures, allowing them to bind clefts, binding sites, and 
enzymatic active sites, which is difficult, if not impossible, for antibodies to achieve (38).  
Nuclease-resistant aptamers that specifically bind to the extracellular domains of 
transmembrane cancer biomarkers, such as integrin avb3, VEGF receptor, EGF receptor, 
HER2, HER3, MUC1, PSMA, and receptor tyrosine kinase RET, can be used to direct 
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nanoparticles to tumor tissues.  Of the reviewed studies (Table 1.1) that used aptamers as 
nanoparticle targeting ligands for cell surface biomarkers, the aptamers were DNA (62%), 
unmodified RNA (17%), or modified RNA (21%).  Compared to numerous RNA nucleases, 
there are relatively few DNA nucleases in vivo.  DNA aptamers do, however, suffer from 
characteristics that can complicate their in vitro selection via SELEX, such as the formation 
of hard to manage G-tetrads.   
Of those studies using unmodified RNA aptamers, two chose nanoparticles that 
confer nuclease resistance to the aptamers.  Li and coworkers employed gold nanoparticles 
(AuNPs), which maintain a halocline immediately surrounding the AuNP and provide a 
blanketing solution layer of high ionic character that discourages nuclease activity (39, 40).  
In another instance, Lee and coworkers found that PSMA-specific RNA aptamer A9, when 
conjugated to dendrimers, was nuclease-resistant 24 hours post-exposure (41).  Exploiting 
A9 nuclease sensitivity, Yu and coworkers intentionally used nucleases as a means of 
releasing intercalated doxorubicin from A9 aptamers targeting nanoparticles to PSMA (42).   
Table 1.1. Recent examples of targeted nanoparticles using aptamers. 	  
PMID#	   Aptamer	   Aptamer	  Type	   Target	   Nanoparticle	   Conjugation	  Chemistry	  15520166	   A10	   Modified	   RNA,	  2'-­‐F	   C/U,	   3'	  inverted	  dT	  cap	   PSMA	   PLA	   Amine/Carboxylate	  16495043	   A9	   Modified	   RNA,	  2'-­‐F	  C/U	   PSMA	   Streptavidin	  Quantum	  Dots	   Hydrazide	  18512972	   A9	   Unmodified	  RNA	   PSMA	   AuNPs	   Base-­‐pairing	  hybridization	  18978032	   A10	   Modified	   RNA,	  2'-­‐F	  C/U	   PSMA	   PLGA-­‐b-­‐PEG	   Amine/Carboxylate	  19377681	   sgc8c	   DNA	   CCRF-­‐CEM	   (T-­‐cell	   acute	  lymphoblastic	  leukemia,	  T-­‐cell	  ALL)	  cells	  
FCNPs	   Amine/Carboxylate	  
20024341	   sgc8	   DNA	   CCRF-­‐CEM	   (T-­‐cell	   acute	  lymphoblastic	  leukemia,	  T-­‐cell	  ALL)	  cells	  
Pegylated	  Liposome	   Thiol/Maleimide	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PMID#	   Aptamer	   Aptamer	  Type	   Target	   Nanoparticle	   Conjugation	  Chemistry	  20066302	   J18	   Unmodified	  RNA	   EGFR	   AuNPs	   Base-­‐pairing	  hybridization	  20080797	   TDO5	   DNA	   immunoglobin	  heavy	  mu	  chain	  receptor	   Aptamer-­‐PEG-­‐Lipid	  NPs	   Non-­‐covalent	  interaction	  20947949	   GB-­‐10	   DNA	   tenascin-­‐c	   Dextran	  Magnetic	  NPs	   Amine/Carboxylate	  21233423	   A10	   Modified	   RNA,	  2'-­‐F	   C/U,	   3'	  inverted	  dT	  cap	   PSMA	   PLGA-­‐b-­‐PEG	   Amine/Carboxylate	  21281497	   apt1	   Unmodified	  RNA,	   2’-­‐OMe	  termini	   CD30	   PEI-­‐citrate	   Non-­‐covalent	  interaction	  21342659	   MUC1	   DNA	   MUC1	   Quantum	  Dot	   Amine/Carboxylate	  21530479	   Ky2	   DNA	   Kanamycin,	  kanamycin	   B,	  tobramycin	   AuNPs	   Non-­‐covalent	  interaction	  21641946	   A9	   Unmodified	  RNA	   PSMA	   PAMAM	  dendrimer	   Base-­‐pairing	  hybridization	  21648076	   A9	   Unmodified	  RNA	   PSMA	   TCL-­‐SPION	   Amine/Carboxylate	  21732610	   MUC1	   DNA	   MUC1	   Three-­‐dimensional	  (3D)	   DNA	  polyhedra	  
Self-­‐assembly	  
21788069	   AS1411	   DNA	   nucleolin	   PEG-­‐PLGA	   Amine/Carboxylate	  21888350	   sgc8	   DNA	   CCRF-­‐CEM	   cell	  line	   PHMNP	   Amine/Carboxylate	  21912664	   MUC1	   DNA	   MUC1	   PLGA	   Amine/Carboxylate	  21936502	   A10	   Unmodified	  RNA	   PSMA	   QD–PMAT–PEI	   Amine/Carboxylate,	  Thiol/Maleimide	  21942498	   sgc8c	   DNA	   CCRF-­‐CEM	   cell	  line	   AuNPs	   Gold/Thiol	  21944470	   AS1411	   DNA	   nucleolin	   Magnetic	  Fluorescence	  NP	  (MF)	   Amine/Carboxylate	  22214176	   XEO2	  mini	   Modified	   RNA,	  2’-­‐OMe	  C/A/U	   PC3,	  LNCaP	   DSPE-­‐PLGA	   Thiol/Maleimide	  22424140	   sgc8c	   DNA	   CCRF-­‐CEM	   cell	  line	   Streptavidin-­‐coated	  MNPs	   Biotin/Streptavidin	  22424140	   TDO5	   DNA	   Ramos	  leukemia	   cell	  line	   Streptavidin-­‐coated	  MNPs	   Biotin/Streptavidin	  22424140	   T2-­‐KK1B10	   DNA	   K562	   leukemia	  cell	  line	   Streptavidin-­‐coated	  MNPs	   Biotin/Streptavidin	  22424140	   KDED2a-­‐3	   DNA	   DLD1	  colon	  cell	  line	   Streptavidin-­‐coated	  MNPs	   Biotin/Streptavidin	  22424140	   KCHA10	   DNA	   HCT116	   colon	  cell	  line	   Streptavidin-­‐coated	  MNPs	   Biotin/Streptavidin	  22424140	   TLS11a	   DNA	   LH86	   liver	   cell	  line	   Streptavidin-­‐coated	  MNPs	   Biotin/Streptavidin	  
 
Many additional iterations of nanoparticle targeting using aptamers have been 
developed over the last several years.  In one of the first instances of pairing aptamers with 
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nanoparticles, Levy and coworkers described the conjugation of a thrombin aptamer to CdTe 
nanocrystal Quantum Dots (QDs) for use as a thrombin sensor via FRET (43).  The design 
involved the synthesis of a secondary sequence that would hybridize with the QD-conjugated 
thrombin aptamer and disrupt conformation.  The secondary sequence featured a quencher 
that obfuscated QD fluorescence.  Binding of thrombin deoppilates the secondary sequence 
quencher, stabilizes proper thrombin aptamer structure, and permits QD fluorescence and 
thrombin binding detection.   
The possibility of aptamer-QD conjugation and targeting was extended by Chu and 
coworkers upon the use of two PSMA aptamers, A9 and A10, previously discovered by 
Lupold and coworkers (44, 45).  These aptamers, which were partially-modified 2’-F-
dCTP/dUTP, were subjected to a procedure developed by Qin and Pyle (1999) involving 3’ 
oxidation with sodium periodate followed by reaction with biotin hydrazide to complete 
aptamer 3’ biotin labeling (46).  The biotin labels permitted aptamer loading onto 
streptavidin-conjugated QD525 nanocrystals.  In another iteration, the nanocrystals were 
PEGylated with HS-PEG 2000 and HS-PEG-biotin 3400.  Biotin-labeled aptamers were 
loaded onto the nanocrystals following avidin coating.  Aptamer-QD nanoparticles proved 
able to label androgen-dependent human prostate adenocarcinoma cells (LNCaP), which 
overexpress PSMA.  The nanocrystals were also tested against three-dimensional 
organotypic (RAFT) LNCaP and PC3 (androgen-independent human prostate 
adenocarcinoma cells) cultures, which are tissue cultures grown in a collagen gel matrix to 
mimic physiology; cells grown on tissue culture plates lack their normal extracellular matrix, 
inducing morphological and functional changes.  PC3, which does not overexpress PSMA, 
yielded little fluorescence, whereas LNCaP did.  Moreover, the aptamer-targeted 
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nanocrystals were able to penetrate the LNCaP RAFT culture to a depth of 200 µm, which 
suggested their suitability in labeling biomarkers deep within tissues.   
AuNPs were found miscible with aptamer targeting approaches by Javier and 
coworkers (47).  The A9 PSMA aptamer was used with a 24 nucleotide extension that could 
hybridize with a thiol-functionalized capture oligo, featuring a C6 S-S spacer and 
hexaethyleneglycol 18-atom spacer on the 5’ end, conjugated to the AuNPs via Au-thiol 
chemistry.  This strategy of loading the A9 aptamer maintained the folded conformation of 
A9 and permitted the specific labeling of LNCaP cells to demonstrate the use of these 
targeted nanoparticles as clinical imaging contrast agents.  In addition, AuNP internalization 
was achieved by Li and coworkers via conjugation of the nanoparticles with EGFR aptamers 
(48).  This strategy took advantage of specific EGFR receptor-mediated endocytosis, 
overcoming the non-specific internalization effect observed with DNA-conjugated AuNPs 
(49).   
More recently, attempts have been made to improve the delivery of chemotoxin-
loaded nanoparticles to solid tumors relying on the FDA-approved strategy of enhanced 
permeability and retention (EPR).  Mann and coworkers designed an amino PEGylated 
liposome and a thiophosphate-backbone modified aptamer (ESTA) against E-selectin, which 
is upregulated in inflamed vasculature, such as that of angiogenic solid tumors (50).  The 
strategy aided EPR nanoparticle tumor accumulation via E-selectin aptamer targeting.  
Conjugation occurred via EDC:NHS amine reactive chemistry with approximately 50% of 
available amines occupied post-reaction.  Pharmacokinetics revealed no significant 
difference in initial volume distribution between naked PEG-liposomes and ESTA-
liposomes.  Clearance rate, however, was affected by about 0.03 µg/h and ESTA-liposome 
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T½ increased from 23 ± 4 hrs for PEG-liposome to 32 ± 7 hrs.  Without any significant 
reduction in bioavailability, Mann and coworkers assert this approach may allow the 
reduction in dosing and drug toxicity.  Similarly, Yu and coworkers used DNA aptamer S2.2 
to target poly(D,L-lactide-co-glycolide) PLGA nanoparticles to MUC1, a transmembrane 
glycoprotein overexpressed in many malignant adenocarcinomas (51).  Aptamer S2.2, with a 
48 nucleotide spacer terminating in an amino group, was conjugated to paclitaxel-loaded 
PLGA nanoparticles via EDC:NHS amine reactive chemistry.  Cell uptake of MUC1-targeted 
nanoparticles was 71% higher in MCF-7 cells (MUC1 overexpressing) compared to HepG2 
(MUC1 non-overexpressing).  Confocal microscopy qualitatively confirmed the presence of 
nanoparticles in MCF-7 cytoplasm.  Aptamer targeting influenced MCF-7 cell viability: 
about 60% versus near-100% in HepG2 cells.  Interestingly, free paclitaxel had almost 
identical effects on MCF-7 and HepG2, yielding cell viabilities of about 90%.   
The direct selection of prostate cancer (PCa) cell internalizing 2’-OMe-
dCTP/dUTP/dATP (rGmH) aptamers was achieved by Xiao and coworkers (52).  Counter 
selection against RWPE-1 (prostate normal epithelial cell line), PrEC (prostate normal 
epithelial cell line), and BPH-1 (prostate benign hyperplastic epithelial cell line) was 
performed prior to selection against PC3 and LNCaP.  The aptamers that did not internalize 
into prostate normal cells were collected and, for the first six rounds of selection, PC3 or 
LNCaP cells were lysed to harvest internalized aptamers.  For rounds 7-12, selection 
stringency was increased via trypsin digestion, thereby removing aptamers bound only to the 
cell surface before lysing the cells.  The 5’-GTP of the selected aptamers was oxidized with 
sodium periodate, producing free aldehydes capable of reaction with the free amine of 
cystamine, conferring thiol groups capable of maleimide-thiol conjugation.  The aptamers 
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were conjugated to hybrid lipid-polymer nanoparticles composed of a PLGA core (for drug 
encapsulation), a lipid monolayer, and a PEG shell conjugated to 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE) for association with the lipid monolayer.  Comparison of 
docetaxel-loaded nanoparticles to aptamer-targeted docetaxel-loaded nanoparticles yielded 
similar toxicities in non-target cells of about 75.33 ± 2.21% and 71.45 ± 3.60% cell viability, 
respectively.  Aptamer targeting yielded enhanced nanoparticle performance with cell 
viabilities of 85.47 ± 3.65% in non-targeted versus 63.10 ± 5.81% in targeted cells.   
Across all reviewed studies, aptamers were conjugated to a variety of nanoparticles 
successfully, as has been done with peptides and antibodies. Unlike peptides and antibodies, 
however, the maintenance of proper aptamer orientation was rarely a problem. Through the 
use of capture oligonucleotides conjugated first to the nanoparticle, followed by 
hybridization of the aptamer via a consensus sequence, or through the synthesis of targeting 
aptamers with a terminal biotin, thiol, or amine, directional conjugation was easily achieved.   
1.3.2 Antibodies 
The idea of using nanoparticle technology as a drug delivery platform antedates 
aptamers, originating from the development and investigation of polyalkylcyanoacrylate 
nanoparticles in the early 1980s (53, 54).  Antibodies were used in this pioneering research 
because, at this time, the work of Pimm and coworkers in the early 1980s notably also 
antedated the development of phage display screening of short peptide libraries (55), yet 
hybridoma technology had existed for almost a decade (56).   
Following Pimm’s work, Vaughan and coworkers developed a method of displaying 
human mAb fragments in a bacteriophage display system (57), which led to the FDA-
approved recombinant human mAb Humira for the treatment of rheumatoid arthritis (58).  
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Another method, described by Russell and Lonberg, created a transgenic mouse whose 
murine antibody genes were replaced by human versions (59, 60). Vectibix, a human anti-
EGFR that can be used to treat colorectal cancer, was developed using transgenic mice (61).  
Other approaches focused on the modification of existing murine mAbs into murine/human 
chimeras for the purpose of improving their pharmacokinetics (62). 
Antibodies, which were considered originally as targeting ligands due to their 
availability for research and their attributes as specific, in vivo targeting ligands without 
reliance on tumor EPR, gained greater utility as nanoparticle targeting ligands from the 
aforementioned advances.  For in vivo therapeutics, the continued use of antibodies as 
nanoparticle targeting ligands is due largely to various developments that have overcome the 
problems of cross-species antibody immunogenicity. Consequently, therapeutic mAb 
development for the purpose of translation to the clinic remains an active field and, therefore, 
mAbs persist as major nanoparticle targeting ligands.   
A review of papers describing antibody-guided nanoparticles (Table 1.2) reveals that 
most targeting antibodies are monoclonal and mostly murine, though some antibodies from 
other species, and polyclonals from rabbit, have been effective, as well as some chimeric (63-
65) and humanized antibodies (66-68).  The majority of these antibodies target the 
extracellular domains (ECDs) of cell surface proteins, which is logical considering their 
intended application as in vivo targeted nanoparticles, the exception being a diagnostic sensor 
of NANOG, a transcription factor, composed of a graphite AuNP-coated film (69).  These 
antibodies have been successfully conjugated to a variety of nanoparticles, from metallic 
nanoparticles (NPs) (e.g. AuNPs, SPIONs, 99mTc), polymers (e.g. PLGA, chitosan, HDDP), 
micelles and liposomes, to silica and QDs.  However, most of the conjugation techniques 
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employed lack directionality, presumably due to the presence of multiple reactive functional 
groups on antibodies, yielding heterogeneous antibody orientations on the nanoparticles.   
Table 1.2. Recent examples of targeted nanoparticles using antibodies. 
 
PMID#	   Antibody	  
Antibody	  
Type	   Source	   Target	   Nanoparticles	  
Conjugation	  
Chemistry	  
22394186	   ab76586	   Monoclonal	  Mouse	  IgG1	   Abcam	   NANOG*	   Graphite	  AuNP-­‐coated	  film	   Amine/	  Carboxylate	  22394186	   ab84231	   Polyclonal	  Rabbit	  IgG	   Abcam	   NANOG*	   Graphite	  AuNP-­‐coated	  film	   Amine/	  Carboxylate	  20825223	   Trastuzumab	   Monoclonal	  Humanized	   	  	   HER2	  ECD	   Magnetic	  nanocrystals	   Non-­‐covalent	  interaction	  18767886	   E2156	   Monoclonal	  Mouse	  IgG1	   Sigma	   EGFR	  ECD	   AuNPs	   Non-­‐covalent	  interaction	  18606202	   mAb62	   Monoclonal	  Mouse	  IgG2a	   	  	   PECAM-­‐1	  ECD	   Polystyrene	   Biotin/	  Streptavidin	  18606202	   mAb35	   Monoclonal	  Mouse	  IgG1	   	  	   PECAM-­‐2	  ECD	   Polystyrene	   Biotin/	  Streptavidin	  18606202	   mAbGi34	   Monoclonal	  Mouse	  IgG1	   	  	   PECAM-­‐3	  ECD	   Polystyrene	   Biotin/	  Streptavidin	  18606202	   mAb4G6	   Monoclonal	  Mouse	  IgG2b	   	  	   PECAM-­‐4	  ECD	   Polystyrene	   Biotin/	  Streptavidin	  18606202	   mAb37	   Monoclonal	  Mouse	  IgG1	   	  	   PECAM-­‐5	  ECD	   Polystyrene	   Biotin/	  Streptavidin	  22107797	   ATCC	  27660	   Polyclonal	  Rabbit	  IgG	   ViroStat	   Staphylococcus	  aureus	   Polylactide	   Non-­‐covalent	  interaction	  
21748635	   Trastuzumab	   Monoclonal	  Humanized	  Mouse	  IgG1	   	  	   HER2	  ECD	   99mTc	   Biotin/	  Streptavidin	  22065745	   29D7	   Monoclonal	  Mouse	  IgG1	   Wyeth	   TrkB	  ECD	   SPIONs	   Rat	   anti-­‐mouse	  IgG1	  capture	  22011314	   Ritux	  (rituximab)	   Monoclonal	  Chimeric	  IgG	   BC	   Cancer	  Agency	   CD20	  ECD	   PEG	  Lipid	  NP	   Thiol/	  Maleimide	  
22114481	   MAB1609	   Monoclonal	  Mouse	   IgG1,	  IgM	   Chemicon	   Cytokeratin	  7/8	  ECD	   SPIONs	   Amine/	  Carboxylate	  
22324543	   7.16.4	   Monoclonal	  Mouse	   UCSF	  Monoclonal	  Antibody	  Core	   Rat	  neu	  ECD	   SPION-­‐chitosan-­‐g-­‐PEG	   Thiol/	  Maleimide	  
22349096	   C225	  (cetuximab,	  erbitux)	   Monoclonal	  Chimeric	  IgG1	   Bristol-­‐Myers	  Squibb	   EGFR	  ECD	   AuNPs	   Amine/	  Carboxylate,	  Au/Thiol	  22410170	   Q5/13	   Monoclonal	  Mouse	  IgG2a	   Beckman	  Coulter	   HLA-­‐DR/DP	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   CD83	   Monoclonal	  Mouse	  IgG1	   Beckman	  Coulter	   HLA-­‐DR/DP	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   CD69	   Monoclonal	  Mouse	  IgG1	   BD	  Biosciences	   HLA-­‐DR/DP	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   CD80	   Monoclonal	  Mouse	  IgG1	   BD	  Biosciences	   HLA-­‐DR/DP	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   CD86	   Monoclonal	  Mouse	  IgG1	   BD	  Biosciences	   HLA-­‐DR/DP	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   CCR7	   Monoclonal	  Rat	  IgG2a	   BD	  Biosciences	   HLA-­‐DR/DP	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   AZN-­‐D1	   Monoclonal	   Alexion	   DC-­‐SIGN	  ECD	   PLGA	   Biotin/	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PMID#	   Antibody	  
Antibody	  
Type	   Source	   Target	   Nanoparticles	  
Conjugation	  
Chemistry	  (αDC-­‐SIGN1)	   Mouse	   hybrid	  IgG2/IgG4	   Pharmaceuticals	   Streptavidin	  
22410170	   AZN-­‐D2	  	   Monoclonal	  Mouse	  IgG2	   Alexion	  Pharmaceuticals	   DC-­‐SIGN	  ECD	   PLGA	   Biotin/	  Streptavidin	  
22410170	   Ab	   hD1	  (αDC-­‐SIGN2)	   Monoclonal	  Humanized	  IgG2/4	   Alexion	  Pharmaceuticals	   DC-­‐SIGN	  ECD	   PLGA	   Biotin/	  Streptavidin	  22410170	   H200	   (αDC-­‐SIGN3)	   Polyclonal	  Rabbit	  IgG	   Santa	   Cruz	  Biotechnology	   DC-­‐SIGN	  ECD	   PLGA	   Biotin/	  Streptavidin	  22464249	   Colo205	   	  Monoclonal	   FMMU,	  China	   EpCAM	  ECD	   Silica	  NPs	   NaIO4	  oxidation	  22464249	   sw480	   	  Monoclonal	   FMMU,	  China	   EpCAM	  ECD	   Silica	  NPs	   NaIO4	  oxidation	  22464249	   NCM460	   	  Monoclonal	   FMMU,	  China	   EpCAM	  ECD	   Silica	  NPs	   NaIO4	  oxidation	  22469295	   9B9	   Monoclonal	  Rat	   ShJU,	  China	   EGFR	  ECD	   PHPA-­‐PEI	   Non-­‐covalent	  interaction	  22494888	   Anti-­‐CD44	   	  Monoclonal	   BD	  Biosciences	   CD44	  ECD	   PEG-­‐Liposome	   Thiol/	  Maleimide	  
22471719	   C225	  (cetuximab,	  erbitux)	   Monoclonal	  Chimeric	   	  	   EGFR	  ECD	   PLGA-­‐ZnS:Mn2+	   Amine/	  Carboxylate	  22515817	   	  	   	  Monoclonal	   BD	  Biosciences	   IL-­‐6	   Fe3O4@SiO2	   Glutaraldehyde	  22515817	   	  	   	  Monoclonal	   BD	  Biosciences	   IFN-­‐γ	   Fe3O4@SiO3	   Glutaraldehyde	  22515817	   	  	   	  Monoclonal	   BD	  Biosciences	   AFP	   (alpha-­‐fetoprotein)	   Fe3O4@SiO4	   Glutaraldehyde	  18239128	   FIB504	   Monoclonal	  Rat	  IgG2a	   	  	   β7	   integrin	  ECD	   Multilamellar	  Liposome	   Amine/Carboxylate	  14512622	   	  	   	  Polyclonal	   	  	   PSA	  ECD	   AuNPs	   Non-­‐covalent	  interaction	  14512622	   	  	   Monoclonal	   	  	   PSA	  ECD	   Iron	  Oxide	  NPs	   Glutaraldehyde/Amine	  
21838300	   anti-­‐TM34-­‐211	   Monoclonal	  Rat	  IgG2a	   	  	   Murine	  thrombomodulin	  ECD	   PEO-­‐filomicelles	   Biotin/	  Streptavidin	  
21838300	   anti-­‐TM201-­‐411	   Monoclonal	  Rat	  IgG2a	   	  	   Murine	  thrombomodulin	  ECD	   PEO-­‐filomicelles	   Biotin/	  Streptavidin	  
21976974	   Trastuzumab	   Monoclonal	  Humanized	  Mouse	  IgG1	   Roche	   HER2	  ECD	   Chitosan	  NPs	   Thiol/Maleimide	  
21976975	   anti-­‐DR5	   Monoclonal	  Humanized	  IgG2b	   Santa	   Cruz	  Biotechnology	   DR5	  ECD	   PLA	   Amine/	  Carboxylate	  
22072868	   LCCS	  Abs	   Polyclonal	  Mouse	   	  	   liver	  cancer	  cell	  surface-­‐specific	  (LCCS)	   AuNPs	   Non-­‐covalent	  interaction	  
22035507	   Anti-­‐Her2	  Ab	   Monoclonal	  Mouse	  IgG1	   Bender	  MedSystems	  (eBioscience)	   HER2	   Iron	  Oxide	  NPs	   Amine/	  Carboxylate	  
21980236	   Anti-­‐EGFR	  Ab	   Monoclonal	  Chimera	   Beijing	   Zhong	  Shan	  Company	   EGFR	   Quantum	   Dots	  (QD800)	   Thiol/Maleimide	  22032622	   ScFv-­‐EGFR	   ScFv	   	  	   EGFR	   HDDP	   Amine/	  Carboxylate	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Antibody targeting of nanoparticles faces several major challenges: antigen binding 
(the mAb must have high target specificity and affinity and the linker, as well as NPs, must 
not perturb the desired specificity), conjugation (the Ab-NP linkage must be highly efficient 
and site-specific), and circulation time (the mAb-NP conjugate linker must be stable during 
circulation). In addition, immunogenicity and purity are other concerns. The body can 
perceive antibodies as foreign proteins and clear them, nullifying the action of the targeted 
NPs. Many conjugation techniques, such as those exploiting lysine side-chain amines and 
cysteine sulfhydryl groups, incite immunogenic responses by yielding heterogeneous 
mixtures of targeted NPs, each with differing Ab:NP molar ratios, conjugation sites, 
pharmacokinetics, and safety profiles. 
1.3.3 Protein Domains 
Targeting ligands based on full-length antibodies have several intrinsic disadvantages 
compared to ligands with much smaller sizes. First, the large sizes of the full-length 
antibodies limit the number of antibody molecules that can be accommodated on the surface 
of nanoparticles. Second, full-length antibodies are composed of multiple light and heavy 
chains that are linked through disulfide bonds. Such structure complicates its expression level 
and makes it difficult to achieve site-specific conjugation with nanoparticles. Third, it is both 
challenging and time-consuming to systematically engineer a full-length antibody with 
optimized targeting-binding parameters. Considerable effort has been directed to the 
reduction of the size of antibodies and the development of smaller binding units with 
antibody-like specificity and affinity. An ideal targeting ligand should be a highly soluble 
small protein with high stability and minimal aggregation, while it can be highly expressed in 
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bacteria with much lower manufacturing costs. In addition, it should possess functional 
residues that facilitate conjugation with nanoparticles, preferably in a site-specific manner.  
The use of antibody fragments represents an interesting compromise in the selection 
of target-specific affinity molecules. The smallest antibody fragments are those based on a 
single domain, such as naturally occurring heavy-chain antibodies found in camelids 
(nanobody) and humans (VH domains) (70-81). These single-domain antibody fragments are 
well expressed, quite soluble and stable, and yet still able to maintain the specificity and 
affinity comparable to scFvs.  
A different approach is to select single domain antibody mimics from partially 
randomized libraries based on protein scaffolds related or not related to natural antibodies 
(82). Scaffolds that have been used to construct single domain protein libraries include 
immunoglobulin-like b-barrel, zinc fingers, a-helical bundles, Src homology domains, PDZ 
domains, various repeat proteins, protease inhibitors, and disulfide-bond constrained small 
toxins (82-89). Among them, targeting ligands based on FN3 (the tenth type III domain of 
human fibronectin), Z domain, and DARPins are most promising (90). Several examples of 
protein domain-based ligands that are suitable for targeted delivery of nanoparticles include 
FN3-based ligands (monobody) that recognize VEGF receptor and integrin avb3, Z domain 
based ligands (affibody) that recognize EGFR and HER2, and DARPin based ligands that 
recognize HER2. 
Compared to the number of nanoparticle applications utilizing antibodies and 
peptides for targeting, relatively few studies have employed protein domains or non-
immunoglobulin antibody mimics (Table 1.3).  These targeting ligands include neurotoxin, 
transferrin, nanobody, affibody, and other protein domains. Though applications are fewer, 
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protein domain nanoparticle targeting is highly promising, as compared to antibodies and 
peptides, for targeted delivery of nanoparticles.   
Table 1.3. Recent examples of targeted nanoparticles using protein domains. 
 
PMID#	   Protein	   Target	   Nanoparticle	  
Conjugation	  
Chemistry	  17964677	   apolipoprotein	   B-­‐100,	   LDLR	   binding	  domain	   LDL	  Receptor	   Micelle	   Non-­‐covalent	  interaction	  18076008	   C-­‐termini	   of	   clostridium/botulinum	  neurotoxins	  (THC,	  BHC)	   GT1b	   ABCD	  NPs	   Thiol/Maleimide	  19173297	   hepatitis	   B	   surface	   antigen	   (HBsAg),	  preS1	  domain	  	   HepG2	  cell	  line	   Micelle	   Ester	  replacement	  20959824	   anti-­‐IGFBP7	   GBM	   PEG-­‐Fe3O4	  NPs	   NHS	  ester	  21306773	   LFA-­‐1,	  I	  domain	   ICAM-­‐1	   Liposome	   Ni/His	  tag	  21609027	   2Rb18a	  nanobody	   HER2	   AuNPs	   Thiol/Maleimide	  21609027	   N7	  nanobody	   PSA	   AuNPs	   Thiol/Maleimide	  21302357	   Affibody-­‐EGFR	   EGFR	   Au-­‐Silica	  NPs	   Thiol/Maleimide	  21508310	   Affibody-­‐EGFR	   EGFR	   Au-­‐Silica	  NPs	   Thiol/Maleimide	  21351748	   Affibody-­‐HER2	   HER2	   Polymeric	  	  nanosphere	   Amine/	  Carboxylate	  21147502	   Affibody-­‐HER2	   HER2	   NIR	   QDs	   and	   IO	  NPs	   Thiol/Maleimide	  20801029	   Affibody-­‐HER2	   HER2	   Bionanocapsules	  (BNCs)	   Genetically	  displayed	  19012296	   Affibody-­‐HER2	   HER2	   PLA-­‐PEG	  polymeric	  NPs	   Thiol/Maleimide	  18937120	   Affibody-­‐HER2	   HER2	   Thermosensitive	  liposomes	   Thiol/Maleimide	  21753879	   adiponectin,	  globular	  domain	  (gAd)	   Atherosclerotic	  plaques	   Proticle	   Non-­‐covalent	  interaction	  21753879	   adiponectin,	  globular	  domain	  (gAd)	   Atherosclerotic	  plaques	   Liposome	   Thiol/Maleimide	  22013169	   anti-­‐IGFBP7	  single-­‐domain	  antibody	   IGFBP7	   SPION	   Amine/	  Carboxylate	  22037106	   Heptameric	  Z	  (EGFR)	   EGFR	   Ni-­‐lipid	  NPs	   Ni2+/His	  tag	  22118776	   Transferrin	   Transferrin	  Receptor	   HSA	  NPs	   Thiol-­‐maleimide	  22410170	   gp120	   DC-­‐SIGN	   PLGA	   Biotin,	  streptavidin	  
 
1.3.4 Peptides 
Much smaller than antibodies but larger than small molecules, short homing peptides 
offer additional nanoparticle targeting options and certain advantages over the 
aforementioned targeting ligands.  The design of a small molecule that fits into a usually 
shallow and hydrophobic binding pocket can be challenging. As a compromise between 
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small molecules and antibodies, short peptides provide smaller size, as well as high 
specificity and affinity. 
Targeting homing peptides are typically discovered via phage display, first developed 
in 1985.  Phage display is a screening tool for peptides, allowing selection of peptide 
sequences with increased affinities to a specific target of choice (91, 92). The phage display 
system is a cyclic selection process where the purified target molecules or specific cell types 
are incubated with a randomized library of peptide sequences displayed on bacteriophage 
capsids.  Some peptides on the capsids bind to the target protein. Non-binders are washed 
away while capsids displaying binding peptides are eluted. Eluted bacteriophages are 
collected, used to infect E. Coli, are amplified, and sent to the next cycle of selection. 
Selected peptides have been used as molecular probes for imaging and can be applied as 
therapeutics as well.  
There are numerous publications using short homing peptides to target nanoparticles 
during the past decade. Studies using peptides as nanoparticle targeting ligands (Table 1.4) 
predominantly utilized ligands discovered via phage display.  Some used natural peptides, 
such as EGF (93, 94), CANF (95), and Angiopep-2 (96).  About 30% of reviewed papers 
used cyclic peptides, though this percentage is influenced by the popularity of the RGD 
peptide as a targeting ligand to αvβ3 integrin (97-102).  All studies targeted cell surface 
proteins.  As with antibodies, the selected peptides were successfully conjugated to a variety  
of nanoparticles, such as metallic NPs (e.g. gadolinium oxide, SPIONs, AuNPs, MBCSPs), 
micelles and polymers (e.g. chitosan, PLGA, poly(methyl methacrylate)), and dendrimers.   
Table 1.4. Recent examples of targeted nanoparticles using short homing peptides. 
 
PMID# Peptide Sequence Cyclic Target Nanoparticle Conjugation 
Chemistry 
21726134 ATWLPPR ATWLPPR  Neuropilin-1 ECD Gd2O3 in Amine/Carboxylate 
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PMID# Peptide Sequence Cyclic Target Nanoparticle Conjugation 
Chemistry 
polysiloxane 
shell 
21740042 EGF   EGFR ECD Vault 
nanoparticles 
Recombinant fusion 
21763734 NGR NGR  CD13 ECD ELP Micelle Non-covalent 
interaction 
21781994 S2P CRTLTVRK
C 
 Stabilin-2 ECD Chitosan Amine/Carboxylate, 
Thiol/Maleimide 
21871505 EGF   EGFR ECD GemC18 NPs Thiol/Maleimide 
21945679 I4R CRKRLDR
NC 
 IL-4R ECD Hydrophobicall
y modified 
glycol chitosan 
Amine/Carboxylate 
21987727 AH1 SPSYVYHQ
F 
 MHC Class II ECD G5-PAMAM 
dendrimer 
Thiol/Maleimide 
21987727 TRP2180–188 SVYDFFV
WL 
 MHC Class II ECD G5-PAMAM 
dendrimer 
Thiol/Maleimide 
21987727 PAn DR 
epitope 
(PADRE) 
aKXVAAW
TLKAAaZC 
 MHC Class II ECD G5-PAMAM 
dendrimer 
Thiol/Maleimide 
21987727 HA110–120 SFERFEIFP
KEC 
 MHC Class II ECD G5-PAMAM 
dendrimer 
Thiol/Maleimide 
22014944 iRGD CRGDKGP
DC 
 αvβ3, αvβ5 PLGA-PLL-
PEG 
Thiol/Maleimide 
22049461 CANF   NPR-C ECD poly (methyl 
methacrylate)-
PEG 
Methacrylate/ 
Acetylene 
22087004  KLWVLPK
GGGC-Am 
 Collagen IV PLGA PEG Thiol/Maleimide 
22093292 CSK CSKSSDYQ
C 
 Goblet cells trimethyl 
chitosan 
chloride 
(TMC) 
Amine/Carboxylate 
22118776 TRAIL hTRAIL(114
–281) 
 DR4, DR5 ECD HSA NPs Thiol/Maleimide 
22133551 Angiopep-2 TFFYGGSR
GKRNNFK
TEEY 
 LRP Receptor ECD PEG-co-
poly(ε-
caprolactone) 
Thiol/Maleimide 
22179825 tLyp-1 CGNKRTR Yes Neuropilin-1/2 ECD Iron oxide 
nanoworms 
(NWs) 
Biotin/Neutravidin 
22196766 Pep 1 CHVLWST
RC 
Yes Pancreatic islet capillary 
endothelial cells 
PLGA-b-PEG Amine/Carboxylate 
22197725 CLL1-L1 CDLRSAA
VC 
Yes CLL1 PEG 
nanomicelle 
telodendrimer 
Click Chemistry: 
Alkyne/Azide 
22375916 RGD cRGDfK Yes αvβ3 integrin AuNPs Amine/Carboxylate 
22396491 OA02 cdG-HoCit-
GPQc-Ebes-
K-alkyne 
 α-3 integrin PEG 
telodendrimer 
Click Chemistry: 
Alkyne/Azide 
22403681 Tet-1 HLNILSTL
WKYR 
 Motor neurons PLGA Amine/Carboxylate 
22497548 RGD cyclic RGD Yes αvβ3 integrin PEG-PEI Electrostatic 
interaction 
22533630 RGD c(RGDyK) Yes αvβ3 integrin UCNP Amine/Carboxylate 
22559746 RGD cRGD Yes αvβ3 integrin CMC Amine/Carboxylate, 
Thiol/Maleimide 
22560667 RGD c(RGDyK) Yes αvβ3 integrin Iron Oxide NPs Thiol/Maleimide 
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PMID# Peptide Sequence Cyclic Target Nanoparticle Conjugation 
Chemistry 
22561668 GRGDS GRGDS  αvβ3 integrin MBCSP 
(PLGA-
magnetite) 
Amine/Carboxylate 
 
Han and coworkers provide an interesting alternative to the typical nanoparticle formulations 
and conjugation paradigms (93).  They expressed targeting peptides recombinantly fused to 
the 97 kDa major vault protein (MVP), which self-assembles into Vault Nanoparticles – 
naturally-occurring nanoparticles present in cell cytoplasm composed of ribonucleoproteins. 
At times, the orientation of the conjugated peptides in the reviewed studies can be 
problematic but this is controlled in some applications at the level of peptide synthesis, 
typically through the additional of a unique functional group to peptide termini, allowing for 
site-specific conjugation with nanoparticles.   
There have been numerous effective in vitro peptides (e.g. targeting protein kinase 
CK2, glioma, FGF receptor, and many others). Finding peptides that work in an in vivo 
setting, however, appears more challenging as they are prone to proteolysis, glomerular 
transit, feature varying toxicities and differential effects on cell signaling, can encourage 
allergic sensitization, and are not amenable to oral bioavailability (103-105).  In addition, the 
costs of peptide synthesis can be prohibitive for some applications (103).   
1.4 The Research Approach Pursued in this Dissertation Directly Selected Highly 
Stable fGmH RNA Aptamers from fGmH Libraries for Use as Targeting Ligands 
To exploit the potentially superior in vivo properties of fGmH RNA aptamers as 
targeting ligands compared to RNAs with fewer 2’ modifications, this study used a mutant 
T7 RNA polymerase to transcribe an initial dsDNA library (i.e. Lib40) into fGmH RNA. The 
mutant T7 RNA polymerase bore the H784A mutation present in the Sousa Variant, as well 
as a K378R mutation, which was reported as potentially silent by Keefe and coworkers and 
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that we confirmed had no discernible effect on catalysis (25, 106). Unlike the Sousa Variant, 
however, this polymerase also bore the Y639L mutation, rather than Y639F. The “LAR” T7 
RNA polymerase used in this study was an attempt to address problems of inefficient non-
canonical ribonucleotide incorporation during in vitro transcription. LAR does not require 
doping of the 2’-X-dNTP pool with 2’-OH-rGTP to produce fGmH RNA with up to 30 to 40 
copies and high quality homogeneous fGmH RNA libraries that are truly directly selectable.  
The selection of fGmH RNA aptamers focused on those that would have the 
properties of enhanced hybridization and nuclease stability, as discussed above, inherent in 
their functionality. The resulting fGmH RNA has some unique features that would greatly 
enhance their suitability for in vivo applications: enhanced stability against many nucleases 
and an inability of most endogenous polymerases to utilize the metabolic products of 
eventual fGmH RNA degradation (Fig. 1.2). In addition, the use of 2’-F residues in RNA 
does not greatly enhance nuclease resistance, which limited the desired number of 2’-F 
residues in the RNA composition pursued in this study. However, the superior ability of 2’-F 
residues to stabilize base pair interactions compared to 2’-OMe prompted us to hypothesize 
that the fGmH RNA composition of one 2’-F and three 2’-OMe residues would have a higher 
probability of achieving greater conformational and nuclease stability for translational 
applications.  
In the following work, Chapter 2 will discuss the selection of fGmH RNA aptamers 
that bind to Staphylococcus aureus Protein A and their employment as targeting ligands for 
the specific delivery of antimicrobial silver nanoparticles. Chapter 3 will describe another 
approach that attempted to select fGmH RNA aptamers against other targets, namely the 
components of the PD-1 immune checkpoint: Programmed Cell Death-1, PD-1 Ligand 1, and 
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PD-1 Ligand 2. Overall, this work will demonstrate the direct selection of aptamers from 
fGmH RNA libraries, provide serum stability comparisons between fGmH RNA aptamers 
and RNAs with fewer 2’ modifications, and employ fGmH RNA aptamers as targeting 
ligands.  
 
Figure 1.2. Diagram of the fGmH RNA described in this work. 
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CHAPTER 2 
SELECTING fGmH RNA APTAMERS FROM A 2’-FULLY MODIFIED fGmH 
RNA LIBRARY THAT BIND Staphylococcus aureus PROTEIN A (SpA) 
 
2.1  Introduction 
The original plan guiding this selection was to select fGmH RNA aptamers in a 
proof-of-concept selection against epidermal growth factor receptor (EGFR) via a 
selection strategy called Active Site – SELEX. This strategy will be described in Chapter 
3, the results of which formed the study described in this chapter. The strategy, however, 
did not select fGmH aptamers against the EGF ligand binding site of EGFR but, instead, 
against the Protein A (SpA) coating the magnetic sepharose beads used for Fc-EGFR 
immobilization. fGmH aptamers that bound SpA were therefore used as proof-of-concept 
for fGmH RNA aptamer technology, as described in the rest of this chapter.  
A fGmH RNA library with a diversity of 7 × 1013 was used in this selection. SpA 
itself is actually an attractive, if not unintentional, selection target because its structure 
and interaction mode with IgG Fc have been well characterized, and because S. aureus 
provides a convenient and relevant biological system for biomaterial development. In 
addition, SpA has become increasingly recognized over the last ten years as a key 
determinant of S. aureus and, especially, MRSA pathogenesis. SpA has binding 
capabilities to a diverse number of host factors, such as many subclasses of IgG Fc, von 
Willebrand Factor (vWF), tumor necrosis factor receptor-1 (TNFR-1), EGFR, and the 
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VH3 class Fabs (107). Most well-known is the protective role that SpA confers to S. 
aureus by neutralizing the humoral response via IgG-Fc binding, thereby preventing 
opsonization. It is clear that highly stable fGmH RNA aptamer anti-SpA nanoparticle 
ligands are desirable as potential therapeutics and reagents for the study of various 
aspects of S. aureus biology.  
2.2  Results 
2.2.1  The Expression and Purification of LAR T7 RNA Polymerase 
As discussed above, it is of great interest to develop a novel class of 2’-fully 
modified RNA aptamers as enhanced biomaterial targeting ligands consisting of a fGmH 
RNA composition. To generate a T7 RNA polymerase mutant that can efficiently accept 
2’-F-dGTP and 2’-OMe-dATP/dCTP/dUTP as substrates, Chuan (Lawrence) Fu 
performed protein engineering to test different combinations of mutant residues reported 
in the literature (8, 25, 27, 28, 108). In so doing, we confirmed that T7 RNA polymerase 
mutant Y639L/H784A/K378R (LAR) was also able to efficiently accommodate a fGmH 
deoxynucleotide mixture as substrates, though this mutant was previously reported 
capable of generating RNA composed entirely of 2’-OMe-deoxynucleotides (MNA) 
(106). Briefly, the cDNA coding the LAR T7 RNA polymerase with the Y639L, H784A, 
and K378R triple mutations was generated by site-directed mutagenesis from the vector 
coding wild-type T7 RNA polymerase (a kind gift from the Sousa lab). The resulting 
cDNA was cloned into a pDest17 vector downstream of the N-terminal 6 x histidine tag 
to facilitate affinity purification. As shown in Figure 2.1, a recombinant protein of 99 
kDa was expressed well and could be purified to homogeneity by using a Co2+-
nitrilotriacetic acid (NTA) column. Potential contamination by nucleases and natural 
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rNTPs was examined on a 20% denaturing PAGE gel. Incubation of 5 pmol aliquots of 
natural RNA with and without purified LAR T7 RNA polymerase did not indicate the 
presence of contaminating nucleases.   
As shown in Lanes 1 to 3 in Figure 2.2, when primed with GMP in the presence 
of PEG-8000, a transcriptional initiator and molecular crowding adjuvant, respectively, 
His-LAR T7 RNA polymerase variant accepted 2’-F-dGTP and 2’-OMe-
dATP/dCTP/dUTP very well, with a relative transcription efficiency of 96% compared to 
an LAR in vitro transcription reaction using all natural 2’-OH-rGTP/rATP/rCTP/rUTP.  
Figure 2.1. Electrophoresis (8%) PAGE gel of the expression and purification of His-LAR T7 RNA 
polymerase. Lanes 1) Induced insoluble fraction, 2) Induced soluble fraction, 3) Uninduced whole cell 
lysate, 4) Molecular weight marker, 5) Molecular weight marker, 6) Induced soluble fraction, 7) Flow-
through of Talon metal affinity column, 8) Buffer A Wash (No imidazole), 9) Buffer B Wash (20 mM 
imidazole), 10) Buffer C Elution 1 (200 mM imidazole), 11) Buffer C Elution 2 (200 mM imidazole). 
 
This contrasts with the various R425 T7 RNA polymerase mutants developed by 
Brakmann and coworkers, which demonstrated 4-fold lower activities in the presence of 
modified nucleotides compared to natural nucleotides (26). We found that 30 to 40 copies 
of fGmH RNA were synthesized by His-LAR T7 RNA polymerase in the presence of 2’-
F-dGTP and 2’-OMe-dATP/dCTP/dUTP (data not shown). When one of the four 2’-X-
dNTPs was not included in the reaction mixture (Lanes 4 to 7), no full-length 
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transcription products were obtained. With the availability of such a T7 RNA polymerase 
mutant, an fGmH RNA library with a diversity of 7 × 1013 unique sequences was 
enzymatically synthesized and purified for in vitro selection.  
Figure 2.2. Transcription efficiency of purified His-LAR T7 RNA polymerase using different 2’-X-
dNTPs. Lane 1) fGmH RNA using 2’-F-dGTP and 2’-OMe-dA/U/CTP, 2) fGmH RNA repeat, 3) natural 
RNA using 2’-OH-rG/A/U/CTP, 4) 2’-OMe-dA/U/CTP, no 2’-F-dGTP, 5) 2’-OMe-dU/CTP, 2’-F-dGTP, 
no 2’-OMe-dATP, 6) 2’-OMe-dA/CTP, 2’-F-dGTP, no 2’-OMe-dUTP, 7) 2’-OMe-dA/UTP, 2’-F-dGTP, 
no 2’-OMe-dCTP. 
 
2.2.2  fGmH RNA Aptamers were Unintentionally Selected against SpA and were 
Characterized for SpA Binding 
To investigate that 2’-fully modified aptamers can be directly selected from an 
fGmH RNA library enzymatically synthesized by LAR T7 RNA polymerase, we 
performed a proof-of-concept selection originally intended against EGFR. However, 
fGmH RNA aptamers were instead selected against S. aureus SpA. SpA serves as a 
model target because of its well-characterized structure, its role as a virulence factor for 
both antibiotic sensitive and resistant S. aureus, and because S. aureus offered a 
convenient and relevant biological system for later demonstrations of fGmH RNA 
aptamer-functionalized AgNPs  (107). Selection utilized magnetic sepharose beads 
immobilized with purified native Protein A via EDC:NHS conjugation with a density 
sufficient for a human IgG binding capacity of 27 mg/mL, as per manufacturer 
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specifications. For each round of selection, the input fGmH RNA library, at ~0.7 µM, 
was incubated with 25 µL (1 column volume) of Protein A beads. Binding was performed 
in 6 column volumes of 1× Aptamer Selection Buffer for 1 h at 4 °C. Beads were then 
washed twice in 6 column volumes of 1× Aptamer Selection Buffer, each for 5 min at 4 
°C. Presumably, the washing (12 column volumes total) removed sequences bound non-
specifically, as well as target-binding sequences with rapid dissociation rates. Aptamers 
were eluted three times from the beads in a total of 18 column volumes of 1× Aptamer 
Selection Buffer, each for 20 min at 4 °C. This longer and extensive elution was designed 
to select aptamers with slower dissociation rates.  
We used the Octet BLI method to monitor the evolution of desired binding 
characteristics within the selected pools during the selection. As shown in Figure 2.3, 
enrichment of the SpA-binding aptamers was not detectable by this binding assay before 
Round 4. Binding was detected in Round 5, with a limited further increase in Round 6. 
Such phenomena are typical for SELEX. Cloning and sequencing, as described, were 
performed on Rounds 5, 6, 7, and 8 selected pools (N = 154) (Fig. 2.4). Despite the small 
sequencing sample size, the evolution of five distinct primary sequence groups was 
evident across these pools.  
Sequences A12, F07, E09, E03, and G12, representing primary sequence groups 
1-5 (Fig. 2.5), respectively, were prepared for kinetic characterization via PCR 
amplification followed by transcription using LAR T7 RNA polymerase. To measure the 
target-binding affinity, fGmH aptamers fmA12 and fmG12 were kinetically characterized 
initially via Biacore SPR using SpA immobilized on CM5 chips. It was found that the 
KDs for fmA12 and fmG12 were approximately 95 nM and 475 nM, respectively (data 
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not shown). These results were confirmed via Octet BLI, and the binding curves 
measured for fmA12, the aptamer extensively used in the remainder of this study, are 
provided in Figure 2.6 and demonstrate saturable and monophasic binding. Due to the 
requirement of examining many different sequences and their variants, subsequent kinetic 
characterizations were performed using Octet BLI, which allowed the binding of 8 
samples to SpA to be measured and analyzed in parallel. As listed in Table 2.1, fmA12 
and fmG12 on Octet yielded KDs of 67.1 ± 6.1 nM and 220 ± 24 nM, respectively, which 
are comparable with those determined by Biacore. BLI analysis for fmF07 and fmE09 
resulted in KDs of 38.9 ± 4.1 nM and 418 ± 112 nM, respectively, whereas fmE03 was 
found to be a non-binding sequence. These fGmH aptamers feature KDs that are 
reproducible in quadruplicate: a property that likely resulted from fGmH sequences 
forming stable structures.    
 
  
 
Figure 2.3. Real-time monitoring of the enrichment of 
fGmH RNA aptamers during the selection using Octet 
BLI. 
 
 
 
 
 
 
Figure 2.4. Percentages of sequences 
classified as one of the five sequence 
motif groups. 
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Figure 2.5. The putative secondary 
structures and random region sequences 
of aptamers fmA12, fmF07, fmE09, and 
fmG12, representing Groups 1, 2, 3, and 
5, respectively. 
 	  	  
Figure 2.6. BLI kinetic characterization 
of fmA12 using biosensors immobilized 
with SpA. 
	  
Table 2.1. Dissociation constants of fGmH RNA aptamers binding S. aureus SpA. 	  
 
 
 
2.2.3  Selected fGmH RNA Aptamers are Specific for SpA, and the fGmH RNA 
Composition is Critical for SpA Affinity 
To test the target-binding specificity of the selected fGmH RNA aptamers, we 
used Octet BLI binding assays to examine the affinity of these aptamers to S. aureus SpA 
and Protein G (SasG), and P. magnus Protein L (PpL), three bacterial proteins that have 
similar IgG binding features. As shown in Figure 2.7, the previously characterized SpA-
binding aptamer fmA12 did not exhibit measurable affinity for SasG or PpL. fmE09 and 
fmG12 yielded similar results (data not shown). fmF07, however, displayed minimal 
Aptamer Group kON (Ms-1) kOFF (µs-1) KD (nM) 
A12 1 12300 ± 207 823 ± 148 67.1 ± 6.1 
F07 2 8810 ± 901 333 ± 17 38.9 ± 4.1 
E09 3 3400 ± 292 1330 ± 276 418 ± 112 
G12 5 4930 ± 345 1080 ± 112 220 ± 24 
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binding to both SasG and PpL, though with much lower affinity than SpA (2.76 ± 2.39 
µM for SasG and 452 ± 92 nM for PpL, compared to 38.9 ± 4.1 nM for SpA). It is 
presumed that fmF07 is capable of binding a structurally conserved region present in all 
three proteins. However, the results for fmA12, fmE09, and fmG12 clearly indicate that 
selected fGmH RNA aptamers are capable of interacting specifically with the target used 
in selection. 
 
Figure 2.7. Binding specificity of 
fmA12 to Protein A, Protein G, and 
Protein L. 
 
 
 
To assess whether the affinity of fGmH RNA aptamers for SpA is dependent on 
2’ modifications, Octet BLI binding assays were performed comparing four A12 RNA 
compositions, each of a different 2’ modification state: rN RNA (every residue bears 2’-
OH; WT A12), fYrR RNA (2’-F modifications on pyrimidines; bmA12), rGmH RNA 
(2’-OMe modifications on A/C/U; tmA12), and fGmH RNA (fmA12). As shown in 
Figure 2.8, only 2’-fully modified fmA12 produced a binding curve matching those 
observed during kinetic characterization, whereas none of the unmodified (WT A12) or 
partially modified (bmA12 and tmA12) exhibited detectable SpA affinity. It is apparent 
that the introduction of 2’-hydroxyls (even when those hydroxyls are restricted to guanine 
residues) into A12 is sufficient to perturb and abolish aptamer binding to SpA. These 
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results indicate that once selected, fGmH RNA aptamers must maintain their 2’ 
modification state to preserve target binding. As such, fGmH RNA aptamers constitute a 
distinct aptamer class. The lack of detectable tmA12 functionality also ruled out the 
concern that fmA12 guanine residues have heterogeneous 2’-hydroxyls, potentially from 
trace contamination of 2’-OH-rGTP in 2’-F-dGTP or rGMP used for transcription. 
 
Figure 2.8. Protein A (SpA) binding 
dependence of sequence A12 on the 
RNA 2’ modification state (WT A12 
(wild-type; rN), bmA12 (fYrR), tmA12 
(rGmH), fmA12 (fGmH)). 
 
2.2.4  fmA12 was Structurally Truncated while Preserving SpA Affinity for 
Potential Future Chemical Synthesis 
All identified SpA-binding aptamers have full-length sequences of 85 residues. 
To map the target-binding regions and facilitate future large-scale chemical synthesis 
using an oligonucleotide synthesizer, the high affinity SpA-binding aptamer fmA12 was 
shortened via comprehensive testing of nine truncation and stem stabilization variants 
(fmA12Δ1 through Δ9). Truncations fmA12Δ1/2/4/5/7/8 resulted in global disruption of 
the putative fmA12 secondary structure, as predicted by Mfold (data not shown). 
Truncations fmA12Δ3/6/9 successfully excised portions of full-length fmA12 without 
disrupting the putative secondary structure (Fig. 2.9). Truncation fmA12Δ3 removed the 
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last five residues at the 3’ end (red sequence in Figure 2.9), which appeared not to be 
involved in the stem or loop secondary structures as predicted by Mfold. Indeed, 
fmA12Δ3 affinity for SpA was preserved compared to full-length fmA12 with a KD of 
69.7 ± 3.5 nM. Truncation fmA12Δ6 maintained Stem-loop Domain I (blue sequence in 
Figure 2.9) but completely removed Stem-loop Domain II (green sequence in Figure 2.9), 
resulting in more than a 1,000-fold reduction in binding affinity (KD of 63.1 ± 7.3 µM). 
Truncation fmA12Δ9 was designed with the fmA12Δ3 acaulescent Stem-loop Domain II 
and the 17-residue single-stranded region at the 5’ end removed (orange sequence in 
Figure 2.9). The resulting fmA12Δ9, with a length of 61 residues, exhibited preserved 
SpA binding with a KD of 69.1 ± 16.7 nM - almost identical to that of the full-length 
fmA12. Sequence truncation analysis indicated, in summary, that Domain I alone is 
insufficient for binding, and, presumably, that both domains are necessary to achieve 
high affinity SpA binding. Overall, sequence truncation found a version of full-length 
fmA12 (fmA12Δ9) that could be chemically synthesized if future need arose. For the 
purposes of this study, no further truncation was necessary though future applications 
may require different sequence length optimizations dependent on the features desired 
from the aptamer.
Figure 2.9. The predicted secondary structures of fmA12Δ3, fmA12Δ6, and fmA12Δ9 compared to that 
of full-length fmA12. 
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2.2.5  fGmH RNA has High Stability against Serum, Alkaline Hydrolysis, and a 
Panel of Individual Nucleases compared to Nucleic Acids of Lower 2’ Modification 
States 
One of the major challenges affecting the potential in vivo application of aptamers 
as biomaterial targeting ligands is the rapid degradation of natural nucleic acids by 
various nucleases present in almost every biological fluid. The enhanced stability of fYrR 
RNA bearing 2’-F modifications on pyrimidines is well known with half-lives of 5 to 15 
hours in serum (5, 7). As mentioned in the Introduction, we pursued the fGmH RNA 
composition for the enhanced hybridization stability conferred by the 2’-F moiety on 
guanine. However, because this moiety does not greatly increase nuclease stability, the 
degradation susceptibility of fGmH RNA was investigated.   
To compare fGmH RNA stability to the known 2’-fluoro-pyrimidine modified 
RNA composition, as well as other RNA compositions, A12 DNA template was 
transcribed into the same previously mentioned four RNA compositions of varying 2’ 
modification state: rN (WT A12), fYrR (bmA12), rGmH (tmA12), and fGmH (fmA12). 
These four A12 RNA variants were incubated in 10% mouse serum at 37 °C over 24 h 
(Fig. 2.10). As expected, the WT A12 variant proved unstable in serum within 5 minutes. 
fmA12 demonstrated much higher stability with 98% survival after five minutes. For 
bmA12, tmA12, and fmA12, gradual losses of the major bands were observed over the 24 
hour incubation, with 31% bmA12, 59% tmA12, and 76% fmA12 surviving after 24 h. 
Linear regression curves fitted to these data indicate a T½ of ~15 h for bmA12, which 
agrees well with that reported in the literature (5). Significantly, regression analysis 
predicts a T½ of ~29.5 h for tmA12 and, significantly, ~52 h for fmA12. Incubation of 
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these RNAs in 50% serum produced similar results (Fig. 2.11). After 2 h, WT A12 is 
completely degraded (not detectable) and 23.7% bmA12, 71.6% tmA12, and 97.4% 
fmA12 survives. fmA12 exhibits a serum stability that is more than 4-fold greater than 
bmA12 after 2 hours. After 5 h, WT A12 is completely degraded (not detectable), bmA12 
is completely degraded (not detectable), and 40.7% tmA12 and 85.0% fmA12 survives. 
Because bmA12 of the canonical fYrR RNA composition was no longer detectable after 
5 hours, no fold comparison is possible between bmA12 and fmA12. However, after 5 
hours, fmA12 proved more than twice as stable as tmA12. These results indicate that 
despite some fmA12 degradation, the 2’-fully modified aptamer variant features superior 
pan-nuclease stability compared to the assayed RNA variants with lower 2’ modification 
states.
Figure 2.10. Percent survival of A12 RNAs of 
varying 2’ modification state in 10% serum (rN 
(WT A12), fYrR (bmA12), rGmH (tmA12), 
fGmH (fmA12)). 
Figure 2.11. Percent survival of A12 RNAs of 
varying 20 modification state in 50% serum after 
2 h and 5 h incubation at 37 °C. 
We further examined the in vitro stability of fGmH RNA aptamers against 
nucleases that degrade RNA via formation of a 2’, 3’-cyclic phosphate intermediate. To 
address this question, G12 DNA was in vitro transcribed into different 2’ modification 
states matching those described above for A12. The four G12 variants were incubated at 
95 °C under alkaline conditions (pH 9.2) for 10 min. Degradation products were observed 
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below the major bands for WT G12, bmG12, and tmG12 (Fig. 2.12). However, fmG12 
did not yield any detectable degradation products under these harsh conditions. Percent 
survival was calculated by quantifying and comparing the treated and untreated fGmH 
RNA major bands, which indicated an fmG12 survival of 99.25 ± 4.86%. The results 
demonstrate that the substitution of all 2’-hydroxyls with a combination of fluoro and O-
methyl groups effectively abrogates degradation by nucleases forming 2’, 3’-cyclic 
phosphate intermediates.  
Figure 2.12. Degradation of G12 RNAs of varying 2’ modification state in alkaline hydrolysis 
conditions.  
 
Neither serum stability assays nor alkaline hydrolysis, however, inform upon the 
ability of individual known nucleases to degrade nucleic acid. For this reason, Lib40 
initial library fGmH RNA was incubated with both deoxyribonucleases and ribonucleases 
at 37 °C for 2 h., 5 h., and 24 h.: DNase RQ1 (DNase I), Exodeoxyribonuclease I (Exo I), 
Exodeoxyribonuclease III (Exo III), T7 Exodeoxyribonuclease (T7 Exo), RNase If, 
RNase A, and RNase T1 (Table 2.2). It appears that fGmH RNA is most resistant to ExoI 
and RNase If, with percent survivals of 100% and 96.2%, after 24 hours, respectively. 
For RNase If, the results are understandable: the presence of 2’-F and 2’-OMe groups 
instead of 2’-hydroxyls will prevent the formation of the 2’,3’-cyclic phosphate 
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intermediate needed for cleavage. RNase A, which like RNase If forms 2’,3’-cyclic 
phosphate intermediates for endonucleolytic cleavage after pyrimidines, demonstrated an 
increased ability to degrade fGmH RNA, yielding a survival of 85.6% after 24 hours. The 
reason for this slight ability to degrade fGmH RNA is not yet known. In addition, it 
interesting that, compared to Exo I, the nucleases DNase I, Exo III, and T7 Exo are able 
to degrade fGmH RNA, with survivals of 85.9%, 84.7%, and 77.7%. None of these four 
deoxynucleases require the presence of a 2’-OH. Logically, however, the active sites of 
these deoxynucleases may have varying abilities to accommodate the 2’-F and 2’-OMe 
moieties on fGmH RNA. Therefore, if these moieties are not accommodated (e.g. steric 
hindrance), as may be the case for Exo I, then no exonucleolytic cleavage would occur. In 
addition, DNase I and Exo III share a mostly conserved active site structure, which 
explains their similar abilities to degrade fGmH (109, 110). RNase T1 sequence and 
tertiary structure has high identity to Barnase, and both use a 2’-OH to position the RNA 
for nucleophilic attack (111, 112). Therefore, the degradation observed (87.2% survival 
after 24 hours) may be due to a lower reaction rate resulting from improper alignment of 
the scissile phosphate in the RNase T1 active site.  
Table 2.2. Percent survival of fGmH Lib40 RNA against individual nucleases. 	  
Time (h.) 
DNase 
RQ1 Exo I Exo III T7 Exo RNase 1f RNase A RNase T1 
0 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2 90.9% 100.0% 100.0% 88.5% 97.4% 91.4% 99.7% 
5 88.0% 100.0% 87.0% 71.2% 96.9% 85.5% 96.1% 
24 85.9% 100.0% 84.7% 77.7% 96.2% 85.6% 87.2% 
 
2.2.6  fmA12 Binds to S. aureus Cells with High SpA Expression 
To demonstrate the biological application of fmA12 as a targeting ligand for 
biomaterials such as AgNPs, confocal microscopy was performed to visualize fmA12 
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binding to S. aureus cells with both high and low SpA expression (113, 114). Full-length 
fmA12 and tmA12, both intercalated with SYBR Green I for signal detection, were 
incubated with S. aureus strains 12598 (high SpA expression) and 10832 (low SpA 
expression). Nonfunctional tmA12 incubation with strain 12598, and functional fmA12 
aptamer incubation with strain 10832 served as negative controls. Incubation of strains 
12598 and 10832 with 10 nM SYBR Green I showed no detectable fluorescent signal, 
indicating that the signal observed later from fmA12 samples was not due to background 
fluorescence (115). As shown in Figure 2.13, 500 nM fmA12 produced a strong 
fluorescent signal upon incubation with high SpA expressing strain 12598. Compared to 
fmA12, 500 nM tmA12 yielded an approximately 90% reduced fluorescent signal upon 
binding to strain 12598. Neither fmA12 nor tmA12 exhibited detectable signal above 
background upon incubation with low SpA expressing strain 10832. These results 
indicate that fmA12 can bind endogenous S. aureus SpA expressed in situ, and fmA12 
can be used for cellular applications.  
2.2.7  Functionalization of AgNPs in Preparation for S. aureus Antimicrobial 
Assays 
As a further demonstration of the applicability of fGmH RNA to in vivo 
applications on biomaterials, fmA12 was used as a targeting ligand for delivery of 
antimicrobial AgNPs to S. aureus cells. AgNPs were chosen because of their diverse 
antimicrobial mechanisms: reactive oxygen species (ROS) generation, bacterial cell wall 
permeability and respiration perturbation via direct contact, and Ag+ shedding resulting 
from oxidation (116). This study used AgNPs with 10 nm average diameter because of 
their superior Ag+ shedding rate compared to those with larger diameters (117). AgNP-
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Aptamer buffer was formulated with acetate salts because AgNP antimicrobial activity 
decreases in buffers containing chloride and phosphate, presumably because silver 
acetate features superior aqueous solubility (Ksp = 1.94 x 10-3) compared to silver 
chloride and silver phosphate (Ksp = 1.77 x 10-10 and 8.89 x 10-17, respectively) (118).  
Figure 2.13. Confocal analysis of the binding of functional fmA12 and non-functional tmA12 to S. 
aureus cells with high (Strain 12598) and low (Strain 10832) SpA expression. 
To introduce fmA12 aptamers to AgNPs, either full-length fmA12 or fmA12Δ9 
functionalized with a 5’ amino group would have been a strategy for direct 
functionalization. However, the presence of a 17 nt region at the 5’ terminus of fmA12 
that was not involved in SpA binding prompted the use of a hybridization approach 
whereby a DNA oligo, antisense to the 5’ terminus of fmA12 and synthesized with a 
primary amine for later conjugation to AgNP surfaces, could serve as both a capture oligo 
and flexible spacer to maintain fmA12 function upon immobilization on the AgNP 
surface. It was found, however, that replacement of GMP during in vitro transcription 
with GMP analogs bearing a 5’ biotin or amine resulted in lower yield (data not shown). 
Fortunately, the 5’ single-stranded region (17 residues) of full-length fmA12 is not 
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necessary for aptamer structure or target binding, as demonstrated during sequence 
truncation analysis. Therefore, we pursued a strategy reliant on enzymatic synthesis for 
the precise and robust generation of both full-length fmA12 and tmA12. This strategy 
was compatible with an antisense oligo hybridization approach that functionalized 
AgNPs with a capture oligo complementary to the 5’ single-stranded region of full-length 
fmA12 and tmA12 (Fig. 2.14). This antisense capture oligo was synthesized with a 3’ 
amine. Reaction of the 3’ amine with carbon disulfide formed a dithiocarbamate, which 
are adsorbed much more strongly onto gold nanoparticles (AuNPs) than monothiols (119, 
120). We found that the capture oligo functionalized with dithiocarbamate was also 
adsorbed very well onto AgNPs. The reaction was characterized via measurement of the 
UV/Vis spectrum (Abs220-750) with a NanoDrop with subsequent analysis of peaks 
produced by AgNPs and capture oligo using the Beer-Lambert Law. Incubation of 
dithiocarbamate-functionalized capture oligos at a 1000:1 molar excess over AgNPs 
while gradually increasing the [Na+] of the conjugation buffer over 28 hours to a final 
concentration of 300 mM yielded a molar ratio of capture oligo:AgNP of ~40:1, a AgNP 
percent recovery of 88% was obtained after conjugation. Conjugation of the capture 
oligos to the AgNPs shifted the absorption maximum of the nanoparticles from 390 nm to 
410 nm and decreased the height of the spectral peak (data not shown), which were 
consistent with observations reported by Tokareva and Hutter (121).  
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Figure 2.14. Diagram of the binding of fmA12-functionalized AgNPs to SpA on the surface of BLI 
biosensors. 
We found that the conjugated capture oligos stabilized the AgNPs in multiple 
physiological buffers, including LB broth, and allowed facile fmA12 docking by sense-
antisense hybridization. This stabilization manifested as the maintenance of a 
characteristic AgNP peak between 390 nm and 410 nm, a visual brown color in solution 
(disperse AgNPs appear brown in solution, whereas aggregated AgNPs become gray), 
and the lack of an AgNP aggregation pellet after centrifugation at 3,000 x g. A 
fmA12:AgNP molar ratio of 10:1 yielded functional binding of the AgNPs to SpA with a 
3 to 4-fold improvement as compared to fmA12 alone. BLI binding analysis showed that 
both ķON and ķOFF of the fmA12 functionalized AgNPs were slower (ķON of 2.68 x 103 
Ms-1; ķOFF of 5.29 x 10-5 s-1) compared to free fmA12 alone (ķON of 1.23 x 104 M-1s-1; 
ķOFF of 8.23 x 10-4 s-1) (Fig. 2.15). The slower fmA12-AgNP association rate could be 
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attributed to the slower diffusion rate of the approximately 60-fold greater molecular 
mass of the AgNPs (1.7 MDa) compared to fmA12 aptamer alone (28 kDa). However, 
the greater than 15-times slower dissociation rate could be due to the avidity effect from 
multiple fmA12 aptamers on the same nanoparticle interacting with SpA on the biosensor 
surface (Fig. 2.15). These results indicate that AgNPs functionalized with fmA12 can be 
used in physiological buffers for targeted delivery of antimicrobial nanoparticle.
 
Figure 2.15. BLI kinetic 
characterization of fmA12-
functionalized AgNP SpA binding. 
 	  	  	  	  	  	  
2.2.8  fmA12 can Deliver AgNPs to S. aureus in a SpA-dependent Manner 
In a further demonstration of fGmH aptamer applicability to in vivo studies, 
fmA12 was used as a targeting ligand for specific delivery of antimicrobial AgNPs to S. 
aureus cells. S. aureus strains 10832 and 12598 were cultured overnight in LB broth as 
described. 1 × 106 CFUs of cells from each strain were incubated under the following 
conditions, in quadruplicate: AgNP-Aptamer buffer only (negative control), citrate-
capped AgNPs alone - not removed from cells during the assay (positive killing control), 
fmA12-functionalized AgNPs, tmA12-functionalized AgNPs (negative control), and 
fmA12 alone (negative control). Each sample used the same concentration of AgNPs 
(except for fmA12 alone, which did not use AgNPs) and A12 RNA (either fmA12 or 
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tmA12, except for positive control, which used non-functionalized, citrate-capped 
AgNPs).  
The killing effect of each preparation above was evaluated by directly counting 
the CFUs and normalizing them against AgNP-Aptamer Buffer Only control. CFU counts 
for the tmA12-functionalized AgNPs negative control were indistinguishable from 
AgNP-Aptamer buffer only control, indicating that non-specific S. aureus cell killing 
from AgNPs was negligible. The same was observed for fmA12 aptamer alone, which 
gave a 93.5 ± 1.1% survival for strain 12598. However, fmA12 aptamer alone gave a 
74.0 ± 2.2% survival for strain 10832 (Fig. 2.16). Though this result was unexpected, it is 
unlikely to be the result of non-specific binding or hydrophobicity. If either of these 
possibilities were real, then fmA12-functionalized AgNP cell killing would have been 
enhanced for Strain 10832 cells to levels equivalent to those observed for Strain 12598 
cells. In addition, fmA12 alone would be expected to induce some cell killing in Strain 
12598 cells. Neither of these results were observed. Instead, fmA12-functionalized 
AgNPs resulted in specific S. aureus antimicrobial activity with only a 1.6 ± 1.0% 
survival of 12598 cells and 51.9 ± 2.0% survival of 10832 cells. High inhibition of strain 
12598 cell growth is likely due to high SpA expression, which would recruit and enhance 
fmA12-targeted AgNPs binding compared to strain 10832, resulting in greater 
antimicrobial action. Some growth inhibition of strain 10832 was not surprising because 
this strain still expresses SpA but at a much attenuated level (114). Overall, fmA12 was 
able to target AgNPs specifically to S. aureus cells and inhibit cell growth in a SpA-
dependent manner. Regarding the apparent reduction of survival for strain 10832 treated 
with fmA12 aptamer alone (74.0 ± 2.2%), this result may be explained by saturation of 
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the low SpA levels present on the surfaces of these cells with fmA12. Schreiber and 
coworkers (2014) recently reported an effect where a SpA-deficient S. aureus strain 
demonstrated reduced adhesion to tested biomaterials due to saturation of available SpA 
by serum immunoglobulins (122). Therefore, it is possible that fmA12 alone saturated the 
SpA available on strain 10832 cell surfaces and slightly affected the ability of this 
bacteria to adhere to LB agar media, leading to smaller colonies and fewer CFU counts. 
This effect, if real, would be even more pronounced for 10832 cells treated with fmA12-
AgNPs due to the larger size of the nanoparticles. Therefore, the 51.9 ± 2.0% survival of 
10832 cells treated with fmA12-AgNPs are due to either increased saturation of available 
SpA or reduced delivery of AgNPs to these cells.  For either of these explanations, the 
effect of fmA12 alone or fmA12-AgNPs on strain 10832 cells is negligible, as would be 
expected for SpA-deficient cells.  
Figure 2.16. S. aureus cell killing effect of fmA12-directed AgNPs based on CFU analysis: 1) AgNP-
Aptamer Buffer only, 2) Citrate-capped AgNPs alone, Unwashed, 3) AgNP-Capture:fmA12, 4) AgNP-
Capture:tmA12, 5) fmA12 alone. 
2.3  Discussion 
The 2’-fully modified RNA aptamers described in this work can be readily 
synthesized using an oligo-synthesizer to introduce a wide variety of functional groups at 
the 5’ or 3’ terminus, including carbonyl-reactive hydrazides or alkyoxyamines, amine-
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reactive activated carboxylates or imidoesters, sulfhydryl-reactive maleimides, 
haloacetyls, pyridyl disulfides, and clickable groups, such as azides, alkynes, or 
phosphines that can undergo bioorthogonal reactions (123). Therefore, many other 
classes of biomaterials or nanomaterials can be targeted with fGmH aptamers, as far as 
they can be functionalized with a chemical group that is compatible with that on the 
aptamer. The chemistry available to aptamers also permits site-specific conjugation to 
biomaterials with correct orientation, a capability that is difficult to achieve for 
antibodies. This property, combined with the high target selectivity demonstrated by 
many aptamers, and the potential for improved bioavailability as suggested by the fGmH 
RNA stability data, indicates that fGmH aptamers would prove superior to peptides, 
protein domains, antibodies, and other targeting ligands in conferring smartness to 
biomaterials in vivo and ex vivo. As this study demonstrates, fGmH aptamers are well-
suited to conferring smartness to silver nanoparticles. It would not be a large logical leap 
to assume that such aptamers would also outperform aptamers of lower 2’-modification 
aptamers and antibody-based affinity molecules that have already been used to 
functionalize various biosensors, including those on atomic force microscopy, graphene, 
BLI, and SPR chips (124-127). fGmH aptamers, specific to a variety of cancer 
biomarkers, could be used to decorate microfluidic platforms or biomimetic hydrogels for 
the capture and potential culture of circulating tumor cells (CTCs) derived from a 
plethora of cancer types, similar to that reported by using EpCAM antibodies (128-130). 
fGmH aptamers could also be logically applied to proteome profiling, particularly the 
highly sensitive single cell detection of cancer cells via a single-cell barcode chip 
(SCBC) (131). In this instance, a single fGmH aptamer bearing a 5’ or 3’ tail can serve 
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both docking and affinity functions, and with lower cost compared to antibodies. Such 
advantages could also improve the performance of lab-on-a-chip approaches, such as 
magnetophoretic digital circuits for single cell or molecular control, and for tuning the 
biological properties of nanofibrous scaffolds and hydrogels used in tissue engineering 
for regenerative medicine (132, 133). 
The concept of direct in vitro selection of 2’-fully modified fGmH aptamers, 
intended for targeted biomaterial delivery, from in vitro transcribed fGmH RNA libraries 
was proven using S. aureus SpA: a structurally well characterized binding partner of 
human Fc, vWF, TNFR-1, EGFR, and VH3 class Fabs. The results obtained from target 
binding analysis clearly demonstrate that fGmH RNA aptamers with high affinity and 
specificity can be directly selected from an fGmH RNA library with high diversity. Prior 
to selection, we hypothesized that RNAs of this 2’-modified composition would have 
enhanced structural stability – a desirable property in an aptamer. The successful 
evolution of fGmH aptamers with high affinity and specificity to SpA proved that, at 
least, this composition did not disrupt the ability of RNA sequences to form stable 
structures. Octet BLI proved invaluable for assaying aptamer pool enrichment. 
Traditionally, the characterization of aptamer pool enrichment requires radio-labeling 
aptamers with either ATP [α-32P] (via in vitro transcription) or ATP [γ-32P] (via 5’ end 
labeling). Transcription using ATP [α-32P] is not desirable for fGmH aptamers because 
the replacement of 2’-OMe-dATP with 2’-OH-ATP [α-32P] would change the 2’ moiety 
of some adenosine residues that would likely disrupt aptamer function. 5’ end 
radiolabeling is compatible with fGmH aptamers, but it adds length to the binding assay 
procedure. Octet BLI, however, is a 96-well plate-based and label-free method of affinity 
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testing that can be performed in parallel for instantaneous measurement and simultaneous 
comparison of samples from different selection rounds. 
Structurally, the four kinetically characterized aptamers resulting from SpA 
selection can be divided into two pairs: high affinity aptamers fmA12 and fmF07, and 
low affinity aptamers fmE09 and fmG12. Within the pairs, aptamers show considerable 
secondary structure similarity (Fig. 2.5), as predicted by MFold, despite significant 
primary sequence differences. fmA12 and fmF07 both have two stem-loop domains, 
whereas fmE09 and fmG12 have only one. Though the SpA epitopes interacting with 
these aptamers are unknown, fmA12 and fmF07 have dissociation constants 5- to 10-fold 
lower than fmE09 and fmG12, implying that the two predicted stem-loop domains could 
be enhancing target binding via avidity.  
Binding of the selected aptamers to SpA does not appear tolerant of post-selection 
replacement of 2’-moieties (fluoro or O-methyl) with hydroxyl groups. When A12 DNA 
was transcribed into rN, fYrR, rGmH, and fGmH RNA, only 2’-fully modified fGmH 
fmA12 demonstrated SpA binding. It is presumed that functional dependence of fmA12 
on the 2’ modification state of fGmH RNA is related to its structure. Specifically, post-
selection replacement of fGmH RNA 2’-moieties with 2’-hydroxyls likely alters intra- 
and/or intermolecular hydrogen bonds (H-bonds), though intramolecular charge 
distributions may also be altered inductively. Unlike 2’-hydroxyls, 2’-F and 2’-OMe 
groups can only accept H-bonds. Post-selection installation of 2’-hydroxyls, acting as 
both H-bond acceptors and donors, have the potential to rearrange the network of 
hydrogen bonds across the entire RNA sequence, thereby altering the aptamer original 
structure. It is likely, however, that short regions or individual residues within an fGmH 
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RNA aptamer are tolerant of 2’-moiety changes. However, fGmH aptamer fmA12 lost 
affinity to SpA upon transcription into RNA variants other than fGmH. In the case of 
rGmH tmA12, where natural 2’-OH-rGTP is used instead of 2’-F-dGTP, every 2’-F 
modified guanine residue was changed to natural guanines. Such substitution, even 
constrained only to guanine residues, would represent a global change to the hydrogen 
bonding network. It is assumed, therefore, that such a change almost always results in 
structural disruption and loss of target binding. It is assumed too that using mixed 
ribonucleotides during transcription (e.g. a mixture of 2’-OH-rGTP and 2’-F-dGTP) 
would yield aptamers with no or reduced affinities. Under such a situation, the 
incorporation of either 2’-OH-rGTP or 2’-F-dGTP at any given position would be 
stochastic or, more likely, that LAR T7 RNA polymerase would preferentially 
incorporate 2’-OH-rGTPs, making it difficult to attribute the loss of binding affinity.  
The direct selection of fGmH RNA libraries nullifies the need for post-selection 
replacement of 2’-hydroxyls, but the selected fGmH RNA aptamers also hold other 
significant advantages over aptamers selected from natural or 2’-partially modified RNA 
libraries. One potential advantage involves chemical synthesis, which is tedious at the 
laboratory scale for natural and 2’-partially modified RNA because 2’-hydroxyls require 
protection and deprotection. In contrast, the 2’-F and 2’-OMe groups on fGmH RNA do 
not require protection. This would potentially greatly simplify chemical synthesis and 
post-synthesis deprotection of the selected fGmH RNAs using protocols as simple as 
those used for DNA.  
Another advantage of fGmH RNA aptamers is that the 2’ modifications enhance 
aptamer resistance to nuclease degradation compared to natural and partially-modified 
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RNA aptamers while introducing a 2’-F moiety for strong H-bond interactions that yield 
greater hybridization stabilization. A significant class of nucleases degrade natural RNA 
(and partially modified RNA to a lesser extent) via a SN2 reaction wherein the 2’-OH 
serves as a nucleophile to form a 2’, 3’-cyclic phosphate intermediate (134, 135). Results 
from harsh alkaline hydrolysis at 95 °C, which mimics this cleavage, demonstrated the 
unusual high stability of selected fGmH RNA aptamers.  
Alkaline hydrolysis, however, is not representative of the plethora of mechanisms 
used by the panoply of nucleases present in biological fluids. fGmH RNA still exhibited 
superior serum stability after 24 hours (76% survival) compared to rGmH RNA (59%), 
fYrR RNA (31%), and rN RNA (~0%), indicating a 17% and 45% increase in survival of 
fGmH RNA over rGmH RNA and fYrR RNA in serum, respectively. The significantly 
increased half-lives of fGmH RNA over the widely used fYrR RNA, in both alkaline 
hydrolysis and serum, clearly indicate that fGmH RNA would be a superior class of in 
vivo reagent compared to fYrR RNA. The minor amount of fGmH RNA degradation 
observed in serum is not surprising considering the presence of numerous nonspecific 
nucleases utilizing various mechanisms of action. Translationally, some nuclease 
sensitivity may be desired because intact fGmH RNA aptamers and their associated 
nanoparticles that persist may yield currently unknown deleterious effects in vivo.  
After successfully proving fGmH RNA aptamer selection and examining the 
stability of fGmH RNA, the biological application of selected fGmH aptamer fmA12 was 
demonstrated. Historically, aptamer affinity for endogenous targets is not certain if in 
vitro selection was performed against a different version of the target protein. For 
example, Sullenger and coworkers found that aptamers selected against purified, 
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recombinant EGFRvIII ectodomain expressed in Escherichia coli were incapable of 
binding endogenous EGFR on cancer cell surfaces due to differences in glycosylation 
(136). Though SpA glycosylation was not a concern here, it was posited that SpA epitope 
structure and accessibility differences could exist between the SpA immobilized on the 
magnetic sepharose beads and endogenous S. aureus SpA on cell surfaces. Cell binding 
analysis using confocal microscopy addressed this concern, revealing that fmA12 could 
bind to endogenous SpA present on S. aureus. This experiment also indicated that fGmH 
RNA aptamers could function in a biologically-relevant environment.  
fmA12 was then applied, as intended, as an AgNP targeting ligand for the 
selective killing of S. aureus cells. AgNPs were chosen for their antimicrobial 
characteristics, especially for the generation of Ag+ that disrupts multiple bacterial 
metabolic processes. Attempts to deliver AgNPs specifically to bacteria in biological 
fluids face a significant challenge: the maintenance of nanoparticle dispersity. Citrate-
capped AgNPs alone aggregated irreversibly upon addition to LB broth or in buffers with 
NaCl as low as 2 mM, as described by the Derjaguin-Landau-Verwey-Overbeek (DLVO) 
theory (137). A stabilizing agent, such as nucleic acids conjugated to the nanoparticle 
surface, is critical when using AgNPs under physiological conditions. To simultaneously 
stabilize and functionalize AgNPs, nanoparticles were first functionalized with a short 
DNA capture oligo. Optimization of capture oligo concentration during AgNP 
conjugation yielded approximately 40 capture oligos per AgNP. At the level of individual 
AgNPs, however, it is likely that functionalization with capture oligos follows a more 
Gaussian distribution, though this was not characterized in this study. Following this 
assumption, the stability of any given functionalized AgNP against [Na+] should also 
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follow this Gaussian distribution. These potential AgNP stability differences, if real, 
however, did not have an effect of sufficient significance to be observed because overall, 
functionalized AgNPs were satisfactorily stabilized in physiological buffers, and featured 
tunable hybridization-mediated aptamer immobilization on AgNP surfaces.  
AgNPs immobilized with fmA12 or tmA12 remained dispersed in buffer, and 
unbound AgNPs were easily separated from the bacterial pellet. Indeed, AgNPs docked 
with nonfunctional tmA12 demonstrated significantly lower bacterial killing compared to 
those docked with SpA-binding functional fmA12. This is because the AgNPs docked 
with tmA12 were easily removed during washing, whereas AgNPs docked with 
functional fmA12 aptamers, which tightly interacted with SpA on S. aureus cell surfaces, 
were not. These results also mitigated concerns that AgNP functionalization would 
interfere with Ag+ shedding. Obviously, either the effect of such interference was non-
existent or not sufficiently strong to be evident in the obtained results. Instead, this study 
determined that the antimicrobial effect produced by functionalized AgNPs, unlike 
aggregated citrate-capped AgNPs, was SpA-dependent and specific.  
In the future, it will be of great interest to study the secondary and tertiary 
structures of fGmH RNA aptamers in greater detail compared to lower 2’ modified 
variants. Such investigations, potentially involving DMS footprinting, x-ray 
crystallography, or NMR structure determination, may yield insights into the hydrogen 
bonding network driving fGmH RNA aptamer structure. In addition, the role, if any, that 
enhanced fGmH RNA hydrophobicity plays in the formation of intermolecular contacts 
should be elucidated. Future studies should focus on the development of fGmH RNA 
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aptamers to other biologically-relevant targets for the expansion of the biomaterial 
targeting repertoire.   
This study has demonstrated the successful direct selection of fGmH RNA 
aptamers with high target binding affinity and specificity from a 2’-fully modified RNA 
library transcribed by a T7 RNA polymerase mutant. Results from stability analysis 
revealed the high stability of fGmH RNA aptamers against alkaline hydrolysis, as well as 
many of the nucleases present in serum as compared to RNAs with different 2’ 
modification states. The selected fGmH RNA aptamers could have great potential in 
conferring smartness to biomaterials as demonstrated by their use as a targeting ligand for 
antimicrobial AgNP delivery to S. aureus cells in a SpA-dependent manner. The system 
described in this work permits the rapid selection of 2’-fully modified fGmH RNA 
aptamers that do not require lengthy and limited 2’ modification after selection. In 
addition, the protection and deprotection of 2’-hydroxyls is completely unnecessary, 
which would greatly facilitate the large-scale chemical synthesis of selected fGmH RNA 
aptamers for translational applications. Overall, fGmH RNA aptamer technology will 
allow the facile identification of highly stable fGmH aptamers that confer smartness to 
biomaterials via a multitude of potential applications.   
2.4  Materials and Methods 
2.4.1  His-LAR T7 RNA Polymerase Expression, Purification, and 
Characterization 
The pDest17 expression vector bearing His-tagged LAR T7 RNA polymerase was 
transformed into E. coli BL21 (DE3) Rosseta cells (Novagen, Darmstadt, Germany). The 
positive clones were selected on LB plates containing carbenicillin (100 µg/mL) and 
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chloramphenicol (34 µg/mL). A single colony was selected and grown in 5 mL of LB 
broth overnight at 37 °C. The resulting culture was added to a flask with 500 mL of LB 
broth containing carbenicillin (100 µg/mL) and chloramphenicol (34 µg/mL). The cells 
were grown at 37 °C until the optical density (Ab600) reached 0.5 to 1.0. IPTG with a 
final concentration of 1 mM was then added to the cell cultures, followed by incubation 
at 22 °C for 16 h. After induction, the cells were spun down at 3,000 × g for 10 min at 4 
°C, and the pellet was stored at −20 °C until use. To purify His-tagged LAR T7 RNA 
polymerase, the cell pellet was resuspended in buffer A (25 mM HEPES pH 7.4 and 300 
mM NaCl) and lysed by sonication for 1 min for a total of 5 times. The soluble fraction 
was recovered by centrifugation at 12,000 × g for 10 min at 4 °C. The resulting fraction 
was loaded onto a TALON metal affinity column (Clontech, Mountainview, CA) pre-
equilibrated with buffer A. Approximately 20 column volumes of buffer A were used for 
initial washing followed by extensive washing (20 column volumes) with buffer B 
(buffer A with 20 mM imidazole). The protein of interest was eluted with buffer C 
(buffer A with 200 mM imidazole). The quality of the purified protein was examined by 
SDS-PAGE. The optimal amount of His-LAR T7 RNA polymerase to be used in each 
reaction was determined on a per batch basis via parallel fGmH RNA transcriptions using 
a serial dilution of the purified enzyme. Transcription products were separated on a 20% 
denaturing PAGE gel, visualized by ethidium bromide staining, and band intensities were 
quantified relative to each other. Purified LAR T7 RNA polymerase was quality 
controlled by checking for nuclease and natural ribonucleotide contamination. Nuclease 
contamination was tested by incubating each LAR T7 RNA polymerase dilution with 5 
pmol of a control natural RNA sequence for 2 h at 37 °C. The presence of contaminating 
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natural ribonucleotides in the purified protein was checked by performing transcription in 
the absence of externally added 2’-X-dNTPs. Transcription products were separated and 
visualized on 20% denaturing PAGE.  
2.4.2  In vitro Selection 
A N40 random fGmH RNA library (Lib40) was generated by transcription from a 
dsDNA library of the following primary sequence: 5’-
TAATACGACTCACTATAGGGAGAGAACAATGACCTG-(N)40-
GAGTGCATTGCATCACGTCAGTAG-3’. The DNA library was constructed 
previously using Klenow Fragment (3’ to 5’ exo-) (New England Biolabs, Ipswich, MA) 
in a reaction mixture of 1.2 mL containing 0.2 mM dNTPs, 0.1 µM single-stranded DNA 
(ssDNA) sequence ssEVS40LB (5’-CTACTGACGTGATGCAATGCACTC-(N)40-
CAGGTCATTGTTCTCTCCCTA-3’), and 0.15 µM ssDNA sequence PDAC-5P (5’-
TAATACGACTCACTATAGGGAGAGAACAATGACCTG), at 37 °C for 1 h. The T7 
promoter sequence is underlined. The initial pool, as well as reverse-transcribed enriched 
aptamer pools during selection, was PCR amplified using 0.5 µM of primers PDAC-5P 
and PDAC-3P (5’- CTACTGACGTGATGCAATGCACTC-3’) and cycling at 95 °C, 62 
°C, and 72 °C for 15 seconds, respectively, for an appropriate number of cycles. In vitro 
transcription of the DNA library using His-LAR T7 RNA polymerase occurred at 37 °C 
for 20 h in an optimized transcription buffer containing 200 mM HEPES, pH 7.5, 2 mM 
spermidine, 2 mM spermine, 19.2 mM MgCl2, 5.8 mM MnCl2, 1.5 mM GMP, 1.5 mM 
2’-F-dGTP, 1.5 mM 2’-OMe-dATP/dCTP/dUTP, 40 mM DTT, and 0.04 U/µL 
thermostable inorganic pyrophosphatase (New England Biolabs, Ipswich, MA). After 
transcription, the reaction mixture was treated with 0.017 U/µL RQ1 RNase-free DNase 
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(Promega, Madison, WI) for 2 h at 37 °C. DNase was inactivated via addition of EDTA, 
pH 8.0 to a concentration 1.2× in excess of Mg2+, and heated at 70 °C for 10 min. The 
fGmH RNA reaction products were ethanol precipitated, desalted, and quantified via 
denaturing PAGE electrophoresis. The initial fGmH RNA library used for selection has a 
diversity of 7 × 1013 unique sequences. 
Prior to target-binding, the initial fGmH RNA library, or regenerated aptamer 
pools, were folded by heating at 80 °C for 3 min followed by incubation in 1× Aptamer 
Selection Buffer (20 mM HEPES, pH 7.4, 150 mM sodium chloride, 5 mM magnesium 
chloride, 1 mM calcium chloride, 1 mg/mL BSA, 0.1 mg/mL yeast tRNA) for 15 min at 
room temperature. Binding of the fGmH RNA library to Protein A Mag Sepharose Xtra 
beads (GE Healthcare, Fairfield, CT) occurred in 6 column volumes of 1× Aptamer 
Selection Buffer (1 column volume = 25 µL) for 1 h at 4 °C. Input fGmH RNA for each 
round of selection was approximately 100 pmol. After incubation, beads were washed 
twice, each with 6 column volumes of 1× Aptamer Selection Buffer for 5 min at 4 °C to 
remove sequences bound nonspecifically. Elution from the beads was performed three 
times, each using 6 column volumes of 1× Aptamer Selection Buffer incubated at 4 °C 
for 20 min to obtain aptamers with slower dissociation rates. Eluted aptamers were 
concentrated and desalted on a Vivaspin 500 5 kDa MWCO centrifugal concentrator 
(Sartorius Stedim Biotech, Bohemia, NY). fGmH RNA recovered from a selection round 
was prepared for reverse transcription by annealing to 2 µM PDAC-3P reverse primer by 
heating at 70 °C for 10 min and immediately cooling on ice for 5 min. After 2 min at 42 
°C, reverse transcription occurred upon addition of 10 U/µL SuperScript II Reverse 
Transcriptase (Life Technologies, Grand Island, NY), in a buffer containing 50 mM Tris-
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HCl, pH 8.3, 0.5 mM dNTPs, 75 mM KCl, 3 mM MgCl2, and 10 mM DTT. cDNA 
products were amplified by PCR as described above for an optimized number of cycles. 
Aptamer pools from Rounds 5, 6, 7, and 8 were ligated into pJET1.2/blunt cloning vector 
(Thermo Scientific, Waltham, MA) and transformed into DH5α E.coli cells for 
sequencing (Eton Bioscience, Durham, NC). Dominant sequences, representing primary 
sequence groups, were selected for in vitro transcription and characterization. The 
secondary structures of sequences of interest were predicted by the online program 
Mfold.  
2.4.3  Binding Analysis Using Surface Plasmon Resonance (SPR) and Biolayer 
Interferometry (BLI) 
Aptamer affinity for S. aureus Protein A (SpA) was measured by using both a 
Biacore 3000 (GE Healthcare, Fairfield, CT) and Octet QK (Pall FortéBio, Menlo Park, 
CA). SPR assays were performed on a Biacore 3000 at room temperature. SpA from S. 
aureus Cowan (Sigma-Aldrich, St. Louis, MO) was pre-concentrated onto CM5 chips by 
injection of 300 µg/mL SpA in 5 mM sodium acetate, pH 4.2 at 10 µL/min. The acidic 
pH of this buffer was below the SpA isoelectric point (pI = 5.16) but above the pKa of 
the carboxyl groups of carboxymethyl dextran, permitting the net positively charged SpA 
to electrostatically interact, and pre-concentrate, with the negatively charged dextran on 
the CM5 chip. With the SpA pre-concentrated against CM5 dextran, covalent 
immobilization of SpA onto the chip occurred via reaction with 200 µL 0.8 M 1-Ethyl-3-
[3-dimethylaminopropyl]carbodiimide (EDC) and 0.2 M N-hydroxysulfosuccinimide 
(NHS) at a 1:1 molar ratio at a flow rate of 10 µL/min at room temperature. The reaction 
was quenched with 1 M ethanolamine at pH 8.0 (10 µL/min and room temperature). SpA 
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immobilization on CM5 chips typically produced ~2500 response units (RUs). Selected 
fGmH RNA aptamers fmA12 and fmG12, human IgG Fc fragment (Athens Research, 
Athens, GA)(positive control), the initial fGmH RNA library and fmE03 (negative 
controls) were analyzed in assay buffer (20 mM HEPES, pH 7.4, 150 mM sodium 
chloride, 5 mM magnesium chloride, 1 mM calcium chloride, 0.005% Tween 20). fGmH 
RNA aptamers were injected into the flow cell at 10 µL/min at 31.25 nM, 62.5 nM, 125 
nM, and 250 nM, respectively. Binding parameters were calculated using BIAevaluation 
software by fitting data using a 1:1 Langmuir binding model.  
The Octet QK is a relatively new, label-free method based on BLI technology that 
measures molecular interactions via fiber optic biosensors (138). Due to its higher 
throughput, greater automation, and lower cost compared to other methods of affinity 
detection, BLI has been applied in the study of more and more molecular interactions 
(139-141). BLI assays were run at 30 °C on an Octet QK using Protein A (ProA) 
biosensors (Pall ForteBio Corp., Menlo Park, CA) and black 96-well microplates. All 
aptamer samples were prepared in assay buffer (as above) and applied to a 96-well 
microplate in column arrangement. An aptamer dilution series tested the following 
concentrations: 157 nM, 313 nM, 625 nM, 1,000 nM, and 1,250 nM. The initial fGmH 
RNA library and non-binding fmE03 were used at 1,250 nM to evaluate nonspecific and 
background binding. Assays were run in quadruplicate. All data were acquired in 
fortéBio Data Acquisition 6.4 software and analyses were performed in fortéBIO Data 
Analysis 6.4 software. Data processing was performed by subtraction of the reference 
sensor signal (assay buffer only), application of Savitzky-Golay Filtering, and global 
curve fitting using a 1:1 model.   
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Other binding assays utilizing the Octet QK were performed under similar 
conditions as above. The binding specificity assay was performed using Protein A 
(ProA), Protein G (ProG), and Protein L (ProL) biosensors, with the major classes of the 
selected aptamers and human IgG Fc fragment positive control at 1.0 µM. The binding of 
A12 aptamer variants with different 2’ modification states was analyzed at 1.0 µM with 
ProA biosensors. Assays assessing the avidity of fmA12-functionalized AgNPs for ProA 
were performed in AgNP-Aptamer Buffer (100 mM HEPES, pH 7.4, 300 mM sodium 
acetate, 10 mM magnesium acetate).  
2.4.4 Aptamer Stability Assays 
fGmH RNA stability in biological fluids started with in vitro transcription of A12 
DNA into four different 2’-modification states: natural 2’-unmodified RNA (rN RNA; 
WT A12), 2’-bi-modified 2’-F-dCTP/dUTP (fYrR RNA; bmA12), 2’-tri-modified 2’-
OMe-dATP/dCTP/dUTP (rGmH RNA; tmA12), and 2’-fully modified 2’-F-dGTP/2’-
OMe-dATP/dCTP/dUTP RNA (fGmH RNA; fmA12). LAR T7 RNA polymerase was 
used to transcribe the fYrR, rGmH, and fGmH A12 variants using the optimized buffer 
system described above, while wild-type T7 RNA polymerase (New England Biolabs, 
Ipswich, MA) was used to transcribe the natural A12 RNA. DNase-treatment, 
precipitation, desalting, and quantification procedures were followed as described above. 
5 pmol of each A12 RNA variant was incubated in 10% mouse serum that was free of 
chelating agents, such as EDTA or citrate (Sigma-Aldrich, St. Louis, MO), for 0 min, 5 
min, 2 h, 5 h, 8 h, 12 h, and 24 h, respectively. All samples after incubation were loaded 
onto a 20% denaturing PAGE for separation, followed by visualization and 
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quantification. Percent survival for each time point was determined via relative 
quantification compared to 0 min time point (5 pmol A12 RNA input).   
Alkaline hydrolysis was performed as a further test of fGmH RNA stability 
against nucleases that form 2’, 3’-cyclic phosphate intermediates. The cDNA template 
coding Aptamer G12 was in vitro transcribed into the same four 2’ modification states as 
described above. 5 pmol of each G12 RNA variant was subjected to incubation at 95 °C 
and pH 9.2 for 10 min (in 50 mM sodium carbonate, pH 9.2, 1 mM EDTA), a condition 
that mimics nuclease degradation (142). Major bands of each RNA composition, both 
treated and untreated, were separated, visualized and quantified via 20% denaturing 
PAGE electrophoresis. Percent survival was calculated by quantitative comparison of 
treated and untreated RNA samples.   
2.4.5  Confocal Microscopy 
S. aureus strains 12598 (high SpA expression) and 10832 (low SpA expression) 
were cultured in LB broth for 12 h at 37 °C. Culture optical density was adjusted to 
McFarland Standard No. 3 (Ab600 = 0.582) in 1 mL LB broth and distributed across 
sample tubes. Bacteria were pelleted via centrifugation at 3,000 × g for 5 min and washed 
with 1× Aptamer Selection Buffer. 500 nM fmA12 and tmA12 were folded as described 
above. SYBR Green I (Life Technologies, Grand Island, NY), a fluorophore that 
intercalates into double stranded nucleic acids for RNA detection and quantification, was 
incubated at 1.0 µM with 0.5 µM folded fmA12 or tmA12 in a total volume of 110 µL for 
30 min at room temperature (115). To minimize fluorescent background, excess free 
SYBR Green I was removed from the fmA12 and tmA12 preparations. fmA12 and 
tmA12 sample volumes were first adjusted to 500 µL in 1× Aptamer Selection Buffer and 
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concentrated to 50 µL using a Vivaspin 500 5 kDa MWCO centrifugal concentrator. The 
samples were then diluted to 500 µL and concentrated to 50 µL a second time. These 
samples, after dilution to 110 µL, had a background SYBR Green I concentration of 10 
nM. Incubation of fmA12 and tmA12 samples with 3,000 colony forming units (CFUs: 
viable bacteria capable of colony formation on LB agar) of S. aureus strain 12598 and 
10832 cells, respectively, occurred at room temperature for 15 min. To remove unbound 
fmA12 and tmA12, the cells were pelleted and washed once with 30 µL of 1× Aptamer 
Selection Buffer at room temperature. Cells were resuspended in 1× Aptamer Selection 
Buffer, mounted with Fluoromount-G on slide glass, and examined using a Zeiss LSM 
710 confocal microscope (Zeiss, Thornwood, NY). 
2.4.6  Silver Nanoparticle Stabilization and Functionalization 
The capture oligo with a 3’ amine was reacted with carbon disulfide to form a 
dithiocarbamate moiety. The reaction occurred at equimolar (50 µM) concentrations of 
capture oligo and carbon disulfide in 400 µL for 2 h at room temperature in 10 mM 
borate buffer, pH 9.0 according to the procedures published by Yan and coworkers (119). 
Free carbon disulfide was removed from the capture oligos via passage through a 
Vivaspin 500 5 kDa MWCO centrifugal concentrator three times in 10 mM borate buffer. 
20 nmol of the resulting capture oligo was incubated with 24 pmol of AgNPs in 95 µL of 
10 mM borate buffer for 12 h at room temperature with constant shaking. The Na+ 
concentration was gradually adjusted to 300 mM by stepwise addition of AgNP 
Conjugation Buffer (100 mM HEPES, pH 7.4, 600 mM sodium acetate, 10 mM 
magnesium acetate) by first increasing the Na+ concentration to 75 mM and incubation 
for 4 h, then to 150 mM (4 h), and then to 300 mM (12 h), and finally storing at 4 °C. 
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Excess capture oligos were removed from AgNPs via repeated dilution and concentration 
using a Vivaspin 500 30 kDa MWCO centrifugal concentrator. Docking and 
immobilization of A12 RNA (fmA12 and tmA12) to AgNPs conjugated with capture 
oligo (AgNP-Capture) occurred at a molar ratio of 10:1 in AgNP-Aptamer Buffer (20 
mM HEPES, pH 7.4, 150 mM sodium acetate, 5 mM magnesium chloride, 1 mM calcium 
chloride) at room temperature for 5 min. AgNPs functionalized with fmA12 and tmA12 
remained dispersed in multiple physiologically relevant buffers, including 1× Aptamer 
Selection Buffer, 1× Aptamer Selection Buffer-Phosphate (chloride ions replaced with 
phosphates), AgNP-Aptamer Buffer, and LB broth.  
2.4.7  Targeted Killing of S. aureus Using SpA-targeted Silver Nanoparticles 
S. aureus strains 12598 and 10832 were cultured and adjusted as above. Prior to 
assay execution, the dispersity and concentration of AgNPs docked with fmA12 or 
tmA12 was confirmed via spectral measurement of the 410 nm peak, with subsequent 
nanoparticle quantification using the molar extinction coefficient reported by Navarro 
and Werts (143). 1 × 106 CFUs of each S. aureus strain were incubated in quadruplicate 
for 2 h at 37 °C (total sample volume of 10 µL) with: AgNP-Aptamer Buffer only 
(negative control), 280 nM fmA12 only (negative control), 91 µg/mL citrate-capped 
AgNPs (positive killing control), 91 µg/mL fmA12-functionalized AgNP-Capture 
(AgNP-Capture:fmA12), and 91 µg/mL AgNP-Capture:tmA12 (negative control), 
respectively. After 2 h incubation, all samples, except citrate-capped AgNP control, were 
pelleted and washed with 10 µL AgNP-Aptamer Buffer. Samples were incubated in LB 
broth for 4 h at 37 °C, followed by 20 h at 25 °C. These growth conditions permitted the 
S. aureus cells in the negative controls to reach McFarland Standard No. 3 (~1 × 109 
	   63	  
CFUs/mL). Dilution of the cultures 1:10,000 ensured proportional plating of 
approximately 100 CFUs per sample if no killing occurred. OD600 values were measured 
for each sample immediately prior to plating. CFUs were counted on each plate after 
overnight incubation at 37 °C. Counted CFUs for each sample were normalized to AgNP-
Aptamer Buffer Only negative control to estimate cell-killing efficiency.  
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CHAPTER 3 
ATTEMPTS TO SELECT fGmH RNA APTAMERS THAT BIND OTHER TARGETS_ 
 
3.1  Introduction 
 The pursuit of this dissertation originally focused on two fGmH RNA aptamer 
selection strategies. The first selection strategy used Active Site – SELEX (developed in 
the Rihe Liu Laboratory) against epidermal growth factor receptor (EGFR), and the 
second selection strategy used SELEX to target Programmed Death 1 (PD-1), PD-1 
Ligand 1 (PD-L1), and PD-1 Ligand 2 (PD-L2), which are members of the PD-1 immune 
checkpoint. The first strategy that targeted EGFR yielded fGmH RNA aptamers that 
bound S. aureus SpA, described in Chapter 2. The second strategy was an attempt to 
extend fGmH RNA aptamer technology to targets of greater biological relevancy to 
cancer, specifically the PD-1 immune checkpoint system that is of intense interest to the 
pharmaceutical industry at large. This chapter will describe these two strategies and 
relevant conclusions resulting from each.  
3.1.1  Strategy 1: fGmH RNA Active Site – SELEX targeting EGFR 
This selection strategy targeted a cause for the diminished clinical performance of 
anti-EGFR tyrosine kinase inhibitors (TKIs) in the treatment of pancreatic ductal 
adenocarcinoma (PDAC) overexpressing EGFR. ErbB3 (HER3) can induce PDAC 
tumorigenesis by heterodimerizing with EGFR, thereby turning on the PI3K/AKT 
signaling pathway and inducing cellular proliferation (144). The ability of the HER3 
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kinase domain to heterodimerize and activate other HER family receptors does not 
require genetic activating mutations and is a known primary cause of ligand-driven 
PDAC proliferation (145-147). Cultured PDAC cells, which also overexpress HER3, 
have been observed undergoing HER3 heterodimerization, thus escaping growth 
inhibition by anti-EGFR TKI erlotinib (144). Significantly, anti-EGFR therapy escape 
was abolished in PDAC in vitro and patient-derived xenograft (PDX) models when anti-
EGFR TKI drug erlotinib and humanized anti-HER3 mAb MM-121 (Merrimack 
Pharmaceutical) were administered in combination (144). Similar in vitro results were 
achieved in squamous cell carcinoma of head and neck (SCCHN) by Bruzzese et al. 
(2010) via the administration of anti-EGFR TKI gefitinib and vorinostat, a histone 
deacetylase (HDAC) inhibitor that modulated HER expression, thereby reducing HER 
heterodimerizations and signal pathway escape (148). Therefore, the selection of fGmH 
RNA aptamers that could disrupt intracellular signaling mediated by EGFR and HER3 
could hold great promise as a highly efficient anticancer therapeutic strategy.  
This selection strategy yielded the SpA binding fGmH RNA aptamers described 
in Chapter 2.  
3.1.2  Strategy 2: fGmH RNA SELEX targeting PD-1, PD-L1, and PD-L2 
Selection Strategy 2 focused on the PD-1 immune checkpoint. A majority of 
human cancers, either constitutively or via IFNγ immune responses, express PD-1 ligand 
1 (PD-L1) or, to a lesser extent, PD-1 ligand 2 (PD-L2) to evade immunosurveillance 
(149-154). Interaction between Programmed Death 1 (PD-1) receptor on activated T 
cells, B cells, and myeloid cells with PD-L1 and PD-L2 leads to immunosuppressive 
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anergy, exhaustion, and apoptosis (150, 153, 155, 156), and counteracts the patient’s 
adaptive immune response to clear the tumor.  
 Immunotherapy attempts to overcome various immunoevasive strategies 
employed by cancers. Of note are attempts to disrupt the antiphagocytic macrophage 
SIRPα:CD47 cancer cell interaction, as well as that between CTLA-4 on T cells and B7.1 
(CD80)/B7.2 (CD86) on cancer cells (157, 158). CTLA-4, historically the first immune 
checkpoint immunotherapeutically investigated, is essential for T cell regulation and the 
prevention of fatal autoimmune disorders observed in CTLA-4 (-/-) knockout mice (159-
161). In clinical trial, severe grade III and IV autoimmunity that caused enteritis and 
hypophysitis was induced by Ipilimumab (anti-CTLA4) (162). PD-1 murine knockouts 
and anti-PD1 (e.g. Nivolumab) and anti-PDL1 (e.g. BMS-936559) antibodies in clinical 
trials have demonstrated lower toxicity (163-166). However, B16 melanoma models have 
shown that blockade of individual immunosuppressive pathways results in upregulation 
of others, revealing the necessity of blocking multiple immunosuppressive pathways 
simultaneously (167). Recent results of a clinical trial combining Nivolumab and 
Ipilimumab have demonstrated a synergistic effect on tumor reduction, similar to that 
observed in vitro by Allison and coworkers (2010), but with 98% of patients experiencing 
adverse events and 49% enduring significant toxicities (168). Though the clinical data is 
promising overall, alternative affinity molecules also targeting the PD-1/PD-L1/PD-L2 
system may be desirable over the existing humanized monoclonal antibodies (mAbs) 
heretofore developed by Bristol-Myers Squib, Merck, and Roche.  
This selection attempted to discover fGmH RNA aptamers that bound to PD-1, 
PD-L1, or PD-L2, and possibly address a major problem facing existing PD-1 and PD-L 
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humanized mAbs: induction of autoimmune responses via blockade of 
immunosuppressive pathways needed to control T cell activity. fmRNA aptamers, which 
could potentially replace these mAbs, feature prolonged serum stability compared to 
RNAs of lower 2’ modification state. This increased stability makes fmRNA aptamers 
uniquely suited to in vivo applications, especially as theranostics. Currently, fmRNA still 
experiences shorter half-lives compared to mAbs, but this characteristic should be 
beneficial because it would limit the time during which T cells are free of homeostatic 
immunosuppression, thereby reducing the risk of inducing autoimmunity.  
3.2  Results for Strategy 2 
 As mentioned previously, the fGmH RNA aptamers selected via Strategy 1 form 
the basis for the fGmH RNA aptamer proof-of-concept selection described in Chapter 2. 
Because these results have already been described in Chapter 2, this Results section will 
only describe findings generated via Selection Strategy 2. Overall, it remains uncertain if 
Strategy 2 was able to select fGmH aptamers against PD-1 and PD-L1 despite the 
resolution of a serious issue that prevented selection success (the domination of selected 
pools by poly A and poly T sequences, called the “poly A/T Effect”, as will be described 
later in this chapter) and the receipt of sequencing data that indicates that the PD-L1 
selection was successful. This section will discuss the testing of hypotheses to overcome 
the poly A/T Effect, the resolution of this Effect, and the selections against PD-1 and PD-
L1 that yielded pools dominated by non-poly A/T sequence motifs.  
3.2.1  Selected Aptamer Pools Became Dominated by poly A and poly T Sequences 
(poly A/T Effect), which is resolved by exchanging the Elution Buffer for Water 
Lib40 initial library fmRNA, with a diversity of 7 × 1013, was obtained and 	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selection was initiated against PD-1. 6 × His-tagged PD-1 was immobilized on GE 
Healthcare His Mag Sepharose beads for Rounds 1 through 5, and on Life Technologies 
His Dynabeads for Rounds 6 through 9. Round 1 was washed with 10 column volumes of 
1 × Aptamer Selection Buffer for 5 min at 4 °C to remove nonspecific sequences; Rounds 
2 and 3 were washed with 2 × 10 column volumes; Round 4 with 4 × 10 column 
volumes; Round 5 with 5 × 10 column volumes; and Rounds 6 and later with 6 x 10 
column volumes. The Round 9 pool, which did not demonstrate binding on Octet, was 
sequenced (Fig. 3.1). Sequencing results indicated that nearly every sequence in the 
sampled pool was poly A or poly T.  
Figure 3.1. Sequencing data for PD-1 Round 9 pool demonstrates poly A/T character (N = 35). 
The following hypotheses were proposed to potentially explain the occurrence of 
the poly A/T effect in the selected pools: 
Hypothesis 1: Natural rATPs and/or rUTPs had contaminated the 2’-OMe-dATP 
or 2’-OMe-dUTP stocks used for fGmH RNA transcription.  
 
In this situation, it is assumed that LAR T7 RNA polymerase would preferentially 
incorporate natural rNTPs into elongating RNAs due to favorable reaction kinetics. These 
in vitro transcription conditions would bias LAR T7 RNA polymerase for rATP or rUTP 
incorporation, potentially yielding poly A/U sequences in the selected pool. 
- GGGAGAGAA CAATGACCTG T C- - - CAGAA ACACA - ACCA AAAAGAAAAA ACACGTGAAT GT TA - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT - - -
- GGGAGAGAA CAATGACCTG T C- - - T GCCA AAACATACCA AAAAAGTACA AAAAAT TAAC AACC- - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AA - - - - GCAA AAGCAAAGAA AATAGATGAA CCATAT CACT CACC- - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG CCAAATATGA AT T CACACCA CAACAGTAAA AAT TAGAAA - - - - A - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG ACAGTAAT CA ATAAATAGCA TAACATAAAA ACT CAACAG- - - - C - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AGCAAAAT CT T CCGACGGCC T TAACTAAAA ATAACCAAG- - - - C - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG CATAAAAAGT TGCAACGT CA AACAAAAAGA CAACACG- - - - T T C - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG T CCAAAAAAT AAGTA - - - - A GAACAAACGA AAAAACCAAT TGCT - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AAACAAACAT GT T CGTGATA TGGAAACT CA AAAACAGTA - - - - C - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG T T T CGAGCGA CAAAA - - - - A GATAAAAGAA AAACT CCGAG GTCA - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG CAACACAACA AAAT T CATGG AAGAAATAAA GCCCAAAAA - - - - T - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG CTAAACAAAA GAAAATAAAA T TGCT T CGCC ACGTATAAA - - - - T - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AT T TGCT CCA CAAGGTCT TA ATAGATAGAT T CGCACG- - - - T CC- - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG - - - - - AACAT T CAAATACCA AAAAAGAGTA ACGTAGACAA ACT TAGAGAG T - - GCAT TGC AT CACG- T CA G- - - AT C - -
- GGGAGAGAA CAATGACCTG AAAAATAAAA GAGCGAAACA TAAATAAT CA GGCAT TATAT - - - - - - T GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AAC- - - - - - - - CT TGAACCA ACAAAAAAGC T T CGCATGAC TAGCGTAGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG GAAAAAAT TA ACAGTAATAA ATAAAAAAGC AT C- - - - - - C CAACGTAGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG TGACAGCCTA ACAAACAAAG TAA - AATAGT T CAAATAA - - - - - - CAAGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AAACGAGAAA TAAAACAATA CAAGAATAAC GCAAACGG- - - - - - T T - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AAA - ATATAA ATGCT CAACA AAGGCACACG GCAATAAGG- - - - - - ACGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AGCTGCAGT T CACAAAAGAC AAAAACAT TG TAAAACAA - - - - - - - CGGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AAT - - - - - - - CT T CGCCACC AAAAAACAGG TCCACTAAAG TAAACCAGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG CAGCT TAAAA AGGAAAAGTA ACAGTAGATA ATAGCACAAC - - - - - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG AAA - AACCT T CGTGCAAAT T AAGAGAAACG AAAAAAGA- - - - - - - - AGAG T - - GCAT TGC AT CACG- T CA T TGT T CT C-
- GGGAGAGAA CAATGACCTG AT T CAGCAAA TACACAAAAC AA - ACAAACG AGAAAACA - - - - - - T CAGAG T - - GCAT TGC AT CACG- - - A T CT T T CTAG
- GGGAGAGAA CAATGACCTG AAAAAAAAAA AGAAAAGGCC TAAATGT CGA TGGCGGCAAA AAT - - - GGAG T - - GCAT TGC AT CACG- T CA G- - - - - - - -
- GGGAGAGAG CAATGACCTG CTATAAAAGT CAAAAGATGC CACTGGT CAA T CTAAA - - - - - - - CT CGGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAAT T CCTGG AAAACAGAAA GCGCAACT CA TGAAAAAAAG GGCTAAGA- - - - - - - CAGAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CAATGACCTG - - - - - - - - - A T T AAAAAACA GAAAAATAAT GCCGCT CT CC AACT CCTAAG T CGACAT TGC AT CACG- T CA GTAGAT C- -
- GGGAGAGAA CA - TGACCTG TACGAAGAT C TGCAACAGAG AAAAGGCACA AAACCCAA - - - - - - - - - AAG AGTGCAT TGG AT CT CG- T CA GTAGAT C- -
- GGGAGAGAG CAATGACCTG AAAAACAACA GCAACTAAAA ATGAAACTGT CT TAT CT - - - - - - - - - - - - - T CCGGAGTGC AT TGCA - T CA AT CTGCTG-
- - - GGGAGAA CAATGACCTG CCAGT CGGT T TAT TACAATG CGACAT TACA CTACCATG- - - - - - - T TGAG T - - GCAT TGC AT CACGAT CT T T CTA - - - -
GGCGAGAGAA CAATGACCTG CGAAAAAGAT AAAAACAAAT CAAACAAACT GCATAGTA - - - - - - - T GGAG T - - GCAT TGC AT CACG- T CA GTAAAT C- -
- GGAAGGAGG CAATGCCAGC AAAAAACACT AAACATAAAA ACAAACAATA AAACT CAG- - - - - - - - - GAG T - - GCAT TGC AT CACG- T CA GTAGAT C- -
- - GGGAGGAG CAATGCCCGG AAACAACTAA AACAAAAACA CAACTGATAT AAAAAT T - - - - - - - CCTGAG T - - GCAT TGC AT CACGT CGA GTAGAT C- -
1
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Hypothesis 2: Prior to PCR, stock solutions of dATPs, dTTPs, dCTPs, or dGTPs 
were cross-contaminated with dATPs or dTTPs.  
 
If the stock tubes of dATP, dTTP, dCTP, dGTP were contaminated with dATP or 
dTTP, or if their actual concentrations varied significantly from that indicated on their 
labels, then there could be higher than intended concentrations of either dATP or dTTP, 
or both, which would kinetically bias Taq DNA polymerase to preferentially incorporate 
dATP or dTTP during polymerization and yielding poly A/T sequences in the selected 
pool. 
Hypothesis 3: The ionic character of the reverse transcription reaction was in 
large excess compared to widely accepted procedures, causing aberrant activity 
by the SuperScript II reverse transcriptase.  
 
SuperScript II is based upon Moloney Murine Leukemia Virus (M-MLV) Reverse 
Transcriptase, which is known to have sensitivity to high cation concentrations (169, 
170). The buffer used to elute 6 × His tagged target proteins from the beads, as well as 
any aptamers bound to the target proteins, contained 150 mM NaCl and 200 mM 
Imidazole, pH 8.0. The elution buffer, however, was not being exchanged for a low ionic 
character buffer (e.g. water). The NaCl and imidazole concentrations were only diluted 
by 50% when added to the reverse transcription reaction (the eluate occupied 50% of the 
RT reaction volume) and, moreover, was being supplemented with additional cations 
from the supplied 5x reaction buffer. Excessive ionic character could be perturbing the 
fidelity of SuperScript II during reverse transcription.  
To test Hypothesis 1, natural RNA in vitro transcriptions using WT T7 RNA 
polymerase were performed in which natural rATP was replaced by 2’-OMe-dATP, and 
natural rUTP was replaced by 2’-OMe-dUTP (Fig. 3.2). When the reaction products were 
visualized on a 20% denaturing TBE PAGE gel, full-length transcripts were only 
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observed for the in vitro transcription reaction that was performed with all four natural 
rNTPs, disproving the hypothesis that rATP or rUTP contamination encouraged the 
formation of selected pools dominated by poly A/T sequences. 
Figure 3.2. Natural rATP/rUTP contamination check in 2’-OMe-
dATP/dUTP stocks using wild-type T7 RNA polymerase. Lane 1) 
DNA template only; 2) natural rNTPs; 3) 2’-OMe-dATP, 
rCTP/rUTP/rGTP; 4) 2’-OMe-dUTP, rATP/rCTP/rGTP. 
 
 
 
To test Hypothesis 2, PCRs were performed on Lib40 initial library, another 
shorter initial library called Lib35, a pJET1.2 vector with insert, and known sequence F07 
that originated from Lib40, all primed with appropriate primers. PCRs on each template 
were performed with one of the four dNTPs missing, a new 10 mM dNTP mixture 
prepared from new dNTP stocks, and the “old” 10 mM dNTP mixture that had been used 
in library generation and all selections thus far (Fig 3.3). Results demonstrated that in the 
absence of any one of the dNTPs, no polymerization occurred, and that polymerization of 
the intended product did occur for all templates with either “old” or new 10 mM dNTPs. 
These results contraindicated the working hypothesis, indicating that no contamination of 
the stock dNTPs with other dNTPs had occurred. 
 
 
 
 
1      2      3       4 
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Figure 3.3. Check for dNTP cross 
contamination of dNTP stocks for PCR. Lane 
1) PCR with no dTTP; 2) PCR with no dCTP; 
3) PCR with no dGTP; 4) PCR with no dATP; 
5) PCR using “current” 10 mM dNTPs freshly 
prepared from new dNTP stocks; 6) PCR 
using “old” 10 mM dNTPs used for all 
selection cycles up to this point; 7) No PCR 
cycling control.	  
  
 
 
 
 
To test Hypothesis 3, a single sequence from the Lib40 library was transcribed 
into both natural RNA and fGmH RNA. These RNAs were used as input material for 
separate reverse transcription reactions. For both natural RNA and fGmH RNA, two 
reverse transcription reactions were performed: one in which the RNA was in DEPC-
treated ddH2O, and the other doped with Elution Buffer. In both conditions, the RNA 
volume was 50% of the RT reaction volume, which is identical to the reaction condition 
used in every selection round. After reverse transcription, PCR titration was performed at 
the same time. For natural RNA, PCR titration of the reverse transcription doped with 
Elution Buffer appeared to delay the amplification of product cDNA by approximately 2 
PCR cycles (data not shown). This effect was not observed for fGmH RNA (data not 
shown). The results suggest that the buffer most likely had an as yet unknown effect on 
the reaction. However, these results assessed relative differences in cDNA yield, not 
cDNA fidelity. Therefore, due to the plausibility that high ionic strength could produce 
aberrant SuperScript II activity, another selection was initiated against PD-1 in which the 
elution buffer was exchanged for DEPC-treated ddH2O prior to reverse transcription. 
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By Round 6, enrichment was observed via PCR (data not shown). Sequencing that 
was performed on Rounds 5, 6, and 7 (Figs. 3.4, 3.5, and 3.6, respectively) revealed that 
Round 5 and 6 pools were not dominated by poly A/T sequences and maintained a high 
degree of sequence diversity, strongly suggesting that Hypothesis 3 was correct. 
Intriguingly, Round 7 sequencing results indicated that selective pressure had driven the 
formation of a single sequence motif group, which represented 75% (N = 24) of the 
sequenced pool. DNA encoding this single sequence, named the PD-1 Dominant 
Sequence, was prepared from the corresponding pJET1.2 colony PCR and in vitro 
transcribed into fGmH RNA. This sequence, however, did not exhibit binding to PD-1 on 
Octet or radiolabeled binding assay.  
Figure 3.4. Sequencing data for reveals that PD-1 Round 5 pool is still highly diverse (N = 31). 
3.2.2  Selective Pressure Successfully Drives the Formation of Sequence Motif 
Groups in an Aptamer Pool Selected against PD-L1; a Single, Non-binding 
Sequence Dominates the PD-1 Selected Pool 
 The dominance of the PD-1 selected pool by a single, non-binding, non-poly A/T 
sequence was hypothesized to be the result of either 1) an unknown characteristic of PD-
1, or 2) the use of a single stationary phase matrix, His Dynabeads. To test both 
hypotheses simultaneously, new selections were initiated against both PD-1 and PD-L1, 
GGGAGAGAAC AATGACCTGG TACGCCACAC AT CGT T CAAC CAACACATGA GGCAAAT CTG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC AAAT CT TACT TACTGCATAA T TAAGAATGA GGGCT T CACG AGTGCAT TGC AT CACGT CAG TAGAT C
- GGGAGAGAA CAATGACCTG CT CTGT CT T T GGTAATAAAC CAAT CAGAAA T T CAAT CAGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC CCTAATGT TG AGT CCT TGT T GT CTAGCCGT T CCT CGT CTG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGG CTAAGGCT TA CCTAT TAGCC AAAAT CGCCA AACGAT CACG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT TACAACAAAC GCGTAAAACC ACCCAAAAGC TGACT CCACG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC AAAT TAT CAA CCCAACCTAA GCT CAAAAAG ACACTGCAGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC AAATACCCCA GTAAGCGTAC CT T CCGAACG TACGT T TAAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC AACGCAACT T GCACT CT TGA GAGCAACT CT AAT T CT TACG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC AACGAT CAT T T CCAACCCAT CTACCCCGCC AGCCTAT T TG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC AT TGCCGACA CT T CGGAT T C T T CCAAGAAG TAGGCCGAGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT CAAT TGCAAA CAAT CAACAA CGTACTGT TA ACGGAAAAGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC GCCT T CTAT T CACT TAAGTG CCAGAAGACA CACT TAGCAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT ATGGTAGGTA T CAGACAT CA AT T TGATAAT T CCAAAGCAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC TAGT CATGAG AT CACTAAGG T TAAAT T TAC CT TACAATGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA T CTAACAGTG ACTAAGCAAA AAGT TGATGG CGAT CT CT TG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA AAAAT CAAAT TAAACATACT AAAT TGACAC T T CT T CGGGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT CCTAACTACT TGCCTACGAC CGCAAAT T CC AAACCCGAAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA CAGT TGCCAA AGTGCCACCT AACCATGGCT T CCT T CCGAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGC T T T T TATGAT AT CT CT TGCA T CGTACGTGC AGATGTGTAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT T TAT TATAGT ATAAAACT CG CAAT T T T TAA CGCACCAGCG AGTGCAT TGC AT CACGT CAG TAGAT C
- GGAGAGAAC AATGACCTGT TACTGAGCAA CCGAAGACCA CCT T TAATAC CTACAT T TAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA ACT T CAT T T T CAGCCGCACT CACGAAGT CA CT T T T CACCG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT AAACGAACAC TAAAATGCT T CAGGCAT TAC ATATGGT CCG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA CTACT CTGTA TAAGACAATG ATAT T T T CAT CTGCGAGATG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGT CGACAAGCAT T T T T T CAAAG T CAGGTCCTG AACTAAAGGG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGA TAAACACTAT T CGT CGAAAG TACT CT CT T T ATGGAAACAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGG TAATATGACG T CTAAAGGAA AT T CAGCTAT T CAT CT CCAG AGTGCAT TGC AT CACGT CAG TAGAT C
GGGAGAGAAC AATGACCTGG AACGAAACCT GT TAAAAAT T CGCCAACCAG ATACAGAACG AGTGCAT TGA T CT T T CTAGA AGAT C-
1
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wherein the bead matrix and protein tag were alternated every two selection rounds. A 
given selection round would use 6 × His tagged target protein immobilized on His 
Dynabeads or Fc chimera target protein immobilized on either Protein A or Protein G 
magnetic sepharose beads. This strategy would discourage the selection of sequences 
binding to either the matrix, matrix-tag interface, or the protein tag.  
Figure 3.5. Sequencing data for reveals that PD-1 Round 6 pool is still highly diverse (N = 31). 
Figure 3.6. Sequencing data reveals that a single sequence dominates the PD-1 Round 7 pool (N = 31). 
Sequencing results from the PD-1 selection indicated that the PD-1 Dominant 
Sequence again dominated the pool (Fig. 3.7). The PD-L1 selection, however, yielded 
very different sequencing results. Rather than one single dominant sequence, the PD-L1 
selected pool hosted seven distinct sequence motif groups (Fig. 3.8). No binding was 
GGGAGAGAAC AATGACCTGC AATACCGGCT T T TGAATATG T TACGTAAAA ACTAGGTCAA GAGTGCAT TG CAT CACGT CA GTAGAT C
GGGAGAGAAC AATGACCTGC AATACCGACT T T TGAATATG T TACGTAAAA ACTAGGTCAA GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG ACTAAAATAC AGTAATAAAC CACAGAAAAC TAT T T TGCAA GAGTGCAT TG CAT CACGT CA GTAGAT C
- - GGGAGAGA ACAATGACCT GCTAACTGCT CATAGGCCAA CCACGCTAT C GCAGGCTGGC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG AATACCCGCT GGTAT CATAT TAGGCAT CGA GACGCGAGCC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG AATACCCGCT GGTAT CATAT TAGGCAT CGA GACGCGAGCC GAGTGCAT TG CAT CACGT CA GTAGAT C
- - - GGGAGAG AACAATGACC TGAT TAGCT C ACTATGACT T T CGCT TGGCT AACTAGCTGC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG GAAAGT CT T T TAAT CATATA CGGAAT T CTA AACTACATAA GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG AT CATACT T C ATAGGCGTGT GACATAAT T C AAAACGAT T T GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG GCCAT T TGCC GACT CGCAAA T T TAT CCACT AT TAGGT TGC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG T TGT T T T T TG CGAAGCGCCG AAT T T TACAA ACAACGCCCC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG AT T CT CACCA AAGT TACAAA GTAGT TGCAA CT CATATGCG GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG T CGCCCAAAA ACTAT CAAAC GCTGAAAACC T T CAAGACAC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG AAT TAACTGC ACCT T CAAAC ACTAT TGTAA CACCGT T CAC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG CAGAAACCCA AAACCCT T TG AACT T TAAT C AAACAAGCAC GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG CCT CACGTGC ACCCAAACGT GT CAAGT T TG CAACCTGCT C GAGTGCAT TG CAT CACGT CA GAT C- - -
- GGGAGAGAA CAATGACCTG CGCAAACAAT T TGAGTAGCA T CGT CT TAAT GTGACGACT C GAGTGCAT TG CAT CACGT CA GTAAT C-
- GGGAGAGAA CAATGACCTG CT CAT T CAAA CCAAGT TAAA ACAT CCTATA TAAGT T CAAA GAGTGCAT TG CAT CACGT CA GTAGAT C
- - GGGAGAGA ACAATACCTG T CGAACACGG CAGACAT CAG AAT CT CT CT C ATAACACT CA GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG AATGT CGACC TAGT TAAACA AATAT CGTAC TAACCAAACA GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG T CTACAACAA GAT CT T T T CA ATAATAAAAC CCCCGAAGT C GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG TAAAAAT TGA T T T TAT TGCT ATAT TAT CAC CT T CCCCT CG GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG TGTAGT CACG GT TGGAAT TG TAACTGCT TG ACAACT T T T C GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG T CGAAAAAAC AT CT CCAT CA CT CAAAGGCG AAAT T CACGG GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG TAACT T TGTA CCGT T TAAAG GAAT CTGCAA GT CCT CTAGC GAGTGCAT TG CAT CACGT CA GTAGAT C
- - - GAGAGAA CAATGACCTG CAAAAAGTAG T CT T TACGCG AACGT T CT T T GT CAGT CAAG GAGTGCAT TG CAT CACGT CA GTAGAT C
- GGGAGAGAA CAATGACCTG T CGACAT CTA GAACCTAAAT TAAAAAATGC ACCGCGACTG GAGTGCAT TG CAT CACGT CA GTAAT C-
- GGGAGAGAA CAATGACCTG TGACT T TAGT GT CAACT CCT TATGTGCT CG CGTACATACG GAGTGCAT TG CAT CACGT CA CTACT - -
- GGGAGAGAA CAATGACCTG TAAAAT TGTG CT T CACTAGT CAT CT T T T CG AGACCGAAGC GACGGCAT TG CACACGT CAG TAGAT C-
- GGGAGAGAA CAATGACCTG CCTAAACCAC ACGAAT T T CG GCCGCAT CT T TAAT T CTAGC GAGTGCAT TA T C- - - - - - - - - - - - - - -
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GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CAGAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCT T CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA T TACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T TGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGCTG GTAT CATAT T AGGCAT CGAG ACGCGAGCCG AGCGCAT TGC AT CACGT CAG TAGAT C-
- GGGAGAGAA CAATGACCTG GATACCCGCG GGT T CATAT T AGGCAT CGAG ACGCGAGCCG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA ATACCCGGTG GTAT CATAT T AGGCAT CGAG ACGCGAGGAG AGTGT T T TGC CACGCGTCAG TAAT C- -
GGGAGAGAAC AATGACCTGT GAGCT TGAAT AT TGGAGAAT AAACT T CAT C GCGCCTAAAG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGT CT CCTAATAC T T CGT CATGA GGTCATACCA TAAT CT CAGG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGA TAT T CAAAAT T CAAT T CAAC AAAAATAAAC T TACAACAAG AGTGCAT TGC AT CACGT CAG TAGAT C-
- GGGAGAGAA CAATGACCTG T CT CAGGTCG AT CAAAAACA T CGAGAATGT CCAAACTGTG AGTGCAT TGC AT CACGT CAG TAGAT C-
GGGAGAGAAC AATGACCTGC TAAAT CCACG GTCAGT CCGG TCACCTGTAA T T CT CAT CCG AGTGCAT TGC AT CACGT CAG TAT CTGC
1
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detected between sequences representing these motif groups and PD-L1 using Octet or 
32P radiolabeled binding assay (data not shown).  
 
Figure 3.7. Sequencing data for reveals that a single sequence dominates the PD-1 Round 7 pool (N = 
31). 
To address the concern that 32P radiolabeling of fmRNA had either failed or was 
too inefficient to detect binding, sequence A12 was transcribed into fGmH (fmA12) and 
natural RNA (WT A12). Radiolabeling was performed on both fmA12 and WT A12 
following the procedure described Section 3.4.2. Radiolabeled products were separated 
on a 20% TBE-Urea PAGE gel, which was stained with ethidium bromide. Input fmA12 
and WT A12 was quantified by comparison to mass standards also run on the gel. A 
Kodak Storage Phosphor Screen sd230 (GE Healthcare, Fairfield, CT) was exposed to the 
gel for 15 min. and imaged on a Typhoon phosphorimager (GE Healthcare, Fairfield, 
CT). ImageQuant software was used to quantify the bands corresponding to 32P 
radiolabeled reaction products. For both fmA12 and WT A12, a normalized ratio of 32P 
labeling to input RNA (32P/input) was calculated. This value, for both fmA12 and WT 
A12, was compared and indicated that 32P 5’ radio-end labeling is 76.0% as efficient for 
fmA12 as WT A12. This result suggests that radiolabeling did not fail and that any 
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reduction in labeling efficiency of fmRNA would not be sufficient to nullify the ability of 
the assay to detect aptamer binding to PD-L1. 
 
Figure 3.8. Sequencing data for reveals that multiple sequence motif groups are present in PD-L1 Round 
8 pool (N = 64). 
3.3  Discussion and Future Directions 
 The pursuit of fGmH RNA aptamers that bound PD-1, PD-L1, or PD-L2 
experienced many unusual problems and produced some conclusive findings. Selected 
DNA aptamer pools became dominated with sequences bearing runs of at least 6 
consecutive A’s or T’s. Binding analyses indicated that these poly A and poly U fmRNA 
sequences were non-binding. The poly A/T effect was found to be library independent as 
well. A shorter library, Lib35, with a length of 66 residues upon transcription was 
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constructed to ease future aptamer truncation and sequence optimization, and was applied 
to selections against PD-1, PD-L1, and PD-L2. Sequencing of the initial Lib35 library 
indicated an acceptable level of base randomness: 23.7% A, 27.9% C, 19.6% G, and 
28.8% T. Sequencing was performed on Round 8 for PD-1 and PD-L1, and Round 7 for 
PD-L2. Poly A and poly T sequences represented 52% of the sequenced PD-1 Round 8 
pool, 65% of the sequenced PD-L1 Round 8 pool, and 22% of the sequenced PD-L2 
Round 7 pool. 
In vitro transcription and PCR experiments confirmed that there was no 
rATP/rUTP contamination of the 2’-OMe-dATP/dUTP stocks used in fGmH 
transcription and that there was no bias by Taq DNA polymerase towards dATP or dTTP 
incorporation during polymerization. After incorporating a buffer exchange in each round 
where the Elution Buffer was exchanged for DEPC-treated ddH2O, the poly A/T effect 
was never again observed in the sequencing data, strongly suggesting that the high ionic 
character of the Elution Buffer had a deleterious effect on the fidelity of SuperScript II 
during reverse transcription.  
 The resolution of the poly A/T effect allowed the enrichment of particular 
sequences in the selected aptamer pools against PD-1 and PD-L1. The PD-1 selected pool 
became dominated by a single non-binding sequence, which is largely without 
precedence and occurred for unknown reasons. For PD-L1, seven non-poly A/T sequence 
motif groups were formed by the selective pressure imposed upon the system. The PD-L1 
selection, therefore, behaved as would be expected if the selection were successful. The 
reason behind the non-binding nature of these sequences, however, remains unresolved. 
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 Glycosylation of PD-1 and PD-L1 was considered as a possible factor that could 
discourage aptamer binding. PD-1 and PD-L1 are heavily glycosylated Type I 
transmembrane proteins that interact via contacts made between residues in their IgV 
domains. Their predicted molecular weights are approximately 14 kDa but migrate 
between 38 and 42 kDa due to glycosylation. PD-L1 binds PD-1 with 1:1 stoichiometry 
at a well-characterized shared binding site; a cleft of 1,915 Å2 formed by residues in the 
GFCC’ strands and the CC’, CC”, and FG loops (Fig. 3.9) (171, 172). Eighteen PD-1 
residues are involved in binding to PD-L2, forming H-bond and hydrophobic contacts: 
V31, N33, Y35, S40, Q42, T43, K45, P56, G57, G91, A92, I93, L95, P97, K98, A99, 
I101, and E103 (residue numbering according to Lazar-Molnar, et al. (2008)). Thirteen 
PD-L1 residues (PD-L2 residue is listed in parentheses when differing from PD-L1) are 
involved in binding to PD-1: F21, D28 (E28), I56 (T56), E60 (Q60), R101 (Q101), M103 
(I103), S105 (I105), G107, A110 (W110), D111, Y112, K113, R114 (Y114). N-
glycosylation is not predicted on residues forming the interface between PD-L1 and PD-
1, nor on those stabilizing the IgC and IgV domains via H-bonds. It is predicted that N-
glycosylation occurs on residues N16, N25, N41, and N83 on PD-1, and on residues N37, 
N175, N183, and N202 on PD-L1. Humanized antibody nivolumab (Opdivo; Bristol-
Myers Squib), which binds to PD-1 and disrupts the PD-1:PD-L1 interaction, binds to an 
epitope that includes N41, one of the sites of putative glycosylation (173). Papers 
reporting PD-1 and PD-L1 structures do not consider O-glycosylation, however, which 
may play a role during expression of these receptors through the secretory pathway (171, 
172). The NetOGlyc 4.0 server (Technical University of Denmark) predicts that residues 
T112, T120, S124, S126, and S240 on PD-1, and S178 on PD-L1 have a high probability 
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of being O-glycosylated (174). None of these predicted sites are in or near the PD-1:PD-
L1 interaction site. Furthermore, expression of PD-1 and PD-L1 in E. coli did not 
completely abrogate PD-1:PD-L1 binding, indicating that glycosylation may not be 
required for PD-1:PD-L interactions but may facilitate complex formation (175, 176). 
When comparing the predicted glycosylation for PD-1 and PD-L1, however, PD-1 would 
appear to be more heavily glycosylated than PD-L1: PD-1 has four sites of N-
glycosylation and five sites of O-glycosylation, whereas PD-L1 has four sites of N-
glycosylation and one site of O-glycosylation. Therefore, it is likely that the overall 
surface of PD-1 is more glycosylated than PD-L1 and that, as a result, PD-1 presents a 
more challenging target for specific aptamer binding than PD-L1. In addition, because 
both N- and O-glycosylation sites oftentimes experience further, heterogeneous 
glycosylation while in the secretory pathway in the Golgi complex, it is likely that 
epitopes favorable for aptamer interaction on some PD-1 and PD-L1 proteins are 
discouraging on others (177). This could potentially make the selection of specific and 
high affinity aptamers more difficult by decreasing the efficiency of the selective pressure 
imposed on selected pools. 
 Heterogeneous glycosylation may not be the correct explanation for the 
observation that certain non-binding sequences dominate both the PD-1 and PD-L1 
selected pools. Therefore, the current direction to resolve the issue of non-binding 
sequence motif groups dominating selected aptamer pools involves the removal of these 
sequences from the PD-L1 selected pool using antisense oligos (ASOs) for RNase H 
degradation. Sequencing results indicated that the selected pool for PD-L1 Round 4 was 
still highly diverse. Therefore, this pool was targeted for ASO-mediated decimation. 
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Performing decimation on later pools (i.e. Round 5, 6, or 7) would be counterproductive 
as most of the sequences in these pools correspond to the identified motif groups. 
According to probability, the diversity left over in these pools would be unlikely to host 
sequences with the desired feature of target binding.  
 
Figure 3.9. Crystal structures of the PD-1 immune checkpoint system. A) Structure of PD-1 showing 
major strands and PD-L2-interacting residues; B) Structure of PD-L2 show major strands and PD-1-
interacting residues; C) Structure of PD-L1 and PD-1-interacting residues for comparison to Fig. 3.9B; 
D) Structure of the PD-1:PD-L2 binding interface. 
 
 To perform ASO-mediated decimation, PD-L1 Round 4 DNA was used for 
natural RNA in vitro transcription using wild-type T7 RNA polymerase and rNTPs. Two 
ASOs were designed for eight sequences targeted for removal: the seven identified motif 
groups and the PD-1 Dominant Sequence. The PD-1 Dominant Sequence had not been 
observed in PD-L1 selected pools but due to its unknown nature of survival, it was 
prophylactically targeted for removal as well. A molar excess of ASOs was annealed to 
RNAs at a ratio of 3:1 in water by heating at 70 °C for 10 minutes and cooling on ice for 
2 minutes. After addition of RNase H (Promega) reaction buffer and RNase H enzyme, 
A	  
B	   C	  
D	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the reaction was incubated at 37 °C for 1 hour. RNase H was then inactivated via heating 
at 65 °C for 20 minutes. ASOs were digested using Exonuclease I. All nucleases were 
removed by phenol:chloroform:isoamyl alcohol extraction. After precipitation and 
flushing three times into water using a 5 kDa MWCO centrifugal filter, the RNA was 
reverse transcribed, entirely as described previously. cDNA was PCR titrated, PCR 
amplified, and in vitro transcribed into fGmH RNA. PD-L1 selection Rounds 5, 6, and 7 
were performed using Round 4 fGmH RNA resultant from ASO-mediated decimation. 
Sequencing data of Round 7 indicates that the selected pool retains a high amount of 
diversity and that no sequences were observed that correspond to any of the motif groups 
targeted for RNase H degradation.  
The presence of high diversity in the PD-L1 Round 7 pool suggests that the 
selective pressure imposed upon this population after ASO-mediated decimation has not 
yet driven the formation of sequence motif groups. There are two plausible reasons for 
this: 1) the sequences that can serve as aptamers with the desired feature of PD-L1 
binding are present but the selective pressure has not sufficient time to select them as 
dominant survivors in the population, or 2) the desired aptamers are not present in the 
population. If the former reason is true, then the future direction is to perform additional 
rounds of selection on this selected pool. Over time, the selective pressure imposed upon 
this pool should preferentially retain those aptamers with desired PD-L1 binding and 
remove those that do not, resulting in a selected pool with multiple copies of the PD-L1 
binding sequences (i.e. new sequence motif groups). However, if the latter reason is true, 
then the diversity of the PD-1 selected pool has been irreconcilably compromised. In this 
case, ASO-mediated decimation should be performed on an earlier PD-L1 selected pool 
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(i.e. Round 1, 2, or 3) or repeated against PD-L1 Round 4 using lower ASO 
concentrations due to the possibility that higher ASO concentrations would encourage 
annealing to RNAs with partial complementarity, allowing RNase H to digest sequences 
not targeted for removal. The diversity of the Lib40 initial library could also have been 
compromised for several reasons, e.g. degradation of the DNA during long-term storage 
at -20 °C, contamination of the library or selected pools with unknown agents, PCR 
amplification of only a subset of the initial library and the use of this DNA as the starting 
material for future aptamer selections. This last reason is not very likely because even if 
only 1 pmol of initial library DNA was amplified, the diversity of the resulting library 
would be 6.022 x 1011, which is 100-fold more diverse than phage display libraries 
limited by transduction rates and that are still successful. If the 1 pmol of initial library in 
this scenario is amplified to 100 pmol, and if 1 pmol of the amplified initial library is 
again used for amplification, then diversity would drop further to 6.022 x 10-9. However, 
it is highly doubtful that the Lib40 library was subjected to such a procedure. 
3.4  Long-term Future Studies 
 To date, no robust and general in silico model yet exists for the ab initio 
prediction of aptamers to a given target. Some attempts have been made over the last ten 
years and have yielded interesting results, but they remain limited, either in their 
modeling of only natural nucleic acids or only aptamer interactions with specific targets. 
In 2007, Ellington and coworkers joined a flavin mononucleotide (FMN) aptamer to a 
hammerhead ribozyme to generate a FMN-dependent aptazyme (178). The study created 
a computational model that predicted base pair slippage resulting from conformational 
changes induced by FMN binding. The best aptazyme predicted by the model was 
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activated 60-fold by FMN. A later effort by Chushak and Stone attempted to predict GTP 
aptamers (179). This was done by selecting sequences from a virtual library that had 
simple stem-loop secondary structures of low free energy. The tertiary structures of these 
sequences were then predicted using the Rosetta package that predicts RNA structure 
based on experimental observations of RNA backbone and side-chain conformation 
preferences (180). The “Docking” portion of the Rosetta package, which simulated 
binding between GTP and predicted aptamers, included known GTP aptamers in the 
predicted top 5% best structures. More recently, Thirumalai and coworkers developed a 
predictive model for bacterial pbuE A-riboswitches (181). However, this study, like the 
others described, was limited to natural nucleic acid compositions and to a very specific 
target. The aptamer field at large would benefit greatly from the development of a robust 
in silico approach for ab initio aptamer prediction against any target, especially one that 
could accommodate fGmH RNA, which replaces 2’-hydroxyls with 2’-OMe on A, C, and 
U residues, and 2’-F on G residues. Though SELEX technology is mature and has been 
modified in many ways to accommodate various in vitro selection strategies, it remains a 
“black box” approach incapable of fully rational design (182).  
 Long-term future studies should focus on the selection of fGmH RNA aptamers 
against other targets. This is necessary because any general predictive model capable of 
predicting the structures of ssDNA and RNAs of multiple 2’ compositions will have to 
account for moiety differences at the 2’ positions. Currently, many DNA aptamers are 
known, as well as natural RNA and fYrR RNA aptamers. However, only the fGmH 
aptamers described in Chapter 2 have been reported in Friedman and coworkers (183). 
Therefore, as mentioned in Chapter 2, X-ray crystal structure or solution phase NMR data 
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of the binding complex between SpA and fmA12, fmF07, fmE09, and fmG12, 
respectively, would shed insights into the interaction modes between these fGmH 
aptamers and SpA. Moreover, fGmH aptamers selected against other targets is critical to 
elucidate a greater repertoire of fGmH RNA interactions with protein and molecular 
targets. With sufficient structural data, an in silico predictive model for ssDNA and RNA 
(e.g. natural, fYrR, fGmH) could be potentially constructed, finally overcoming the 
“black box” of SELEX and moving aptamer technology into an era of rapid and rational 
design.  
3.4  Materials and Methods 
 The Materials and Methods for Strategy 1 (EGFR Active Site – SELEX) are 
identical to those described in Chapter 2. Therefore, this section will only describe the 
Materials and Methods for Strategy 2 (PD-1, PD-L1, and PD-L2 SELEX).  
3.4.1  In vitro Selection 
As in Chapter 2, LAR T7 RNA polymerase and a N40 random fGmH RNA 
library (Lib40) was used for aptamer selections. A N35 random fGmH RNA library was 
also generated for aptamer selections by transcription from a dsDNA library of the 
following primary sequence: 5’-
CTAATACGACTCACTATAGGGAGAGAGACGAGC-N(35)-
GCTCGCCTCGCTCAGC-3’. The DNA library was constructed using Klenow Fragment 
(3’ to 5’ exo-) (New England Biolabs, Ipswich, MA) in a reaction mixture of 1.2 mL 
containing 0.2 mM dNTPs, 1 µM single-stranded DNA (ssDNA) sequence PD1-35N (5’-
GCTGAGCGAGGCGAGC-N(35)-GCTCGTCTCTCTCCC-3’), and 1.5 µM ssDNA 
sequence PD1-Fwd (5’-CTAATACGACTCACTATAGGGAGAGAGACGAGC-3’), at 
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37 °C for 1.5 h. The T7 promoter sequence is underlined. The initial pool, as well as 
reverse-transcribed enriched aptamer pools during selection, was PCR amplified using 
0.5 µM of primers PD1-Fwd and PD1-Rev (5’- GCTGAGCGAGGCGAGC-3’) and 
cycling at 95 °C, 58 °C, and 72 °C for 15 seconds, respectively, for an appropriate 
number of cycles. In vitro transcription of the DNA library using His-LAR T7 RNA 
polymerase, DNase I-treatment, precipitation, desalting, and quantification were 
performed as in Chapter 2. The initial fGmH RNA library used for selection has a 
diversity of 1 × 1014 unique sequences. 
Prior to target-binding, the initial fGmH RNA library, or regenerated aptamer 
pools, were folded by heating at 80 °C for 3 min followed by incubation in 1× Aptamer 
Selection Buffer (50 mM HEPES, pH 7.4, 150 mM sodium chloride, 5 mM magnesium 
chloride, 1 mM calcium chloride, 1 mg/mL BSA, 0.1 mg/mL yeast tRNA) for 15 min at 
room temperature. Per round of selection, 10 µg of the target protein (i.e. His-PD1, His-
PDL1, His-PDL2, Fc-PD1, Fc-PDL1, Fc-PDL2) were immobilized to a bead matrix. For 
the first selection attempt and Rounds 1 through 5 of the second selection attempt, His-
tagged proteins were immobilized on His Mag Sepharose Beads (GE Healthcare, 
Fairfield, CT) for 2 h. at 4 °C. For Rounds 6 through 9 of the second selection attempt, all 
rounds of the third selection attempt, and those rounds utilizing His-tagged protein in the 
fourth selection attempt, His-tagged proteins were immobilized on His-Tag Dynabeads 
for 2 h. at 4 °C. In the fourth selection attempt, some rounds utilized Fc-chimera proteins, 
which were immobilized on either Protein A or Protein G Mag Sepharose Xtra beads (GE 
Healthcare, Fairfield, CT) for 2 h. at 4 °C. Binding of the fGmH RNA libraries to the 
immobilized target protein occurred in 25 column volumes of 1× Aptamer Selection 
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Buffer (1 column volume = 25 µL) for 1 h at 4 °C. Input fGmH RNA for each round of 
selection was approximately 100 pmol. After incubation, beads were washed according to 
selection round; typically, Round 1 was washed with 10 column volumes of 1× Aptamer 
Selection Buffer for 5 min at 4 °C to remove sequences bound nonspecifically, Rounds 2 
and 3 were washed with 2 × 10 column volumes, Round 4 with 4 × 10 column volumes, 
Round 5 with 5 × 10 column volumes, and Rounds 6 and later with 6 x 10 column 
volumes. Elution from the beads was performed twice using 75 column volumes of either 
200 mM imidazole, 150 mM NaCl, pH 8.0 if using His-tagged protein or 100 mM 
glycine, pH 2.5 if using Fc-chimeras. Beads were incubated in elution buffer at 4 °C for 
20 min to obtain aptamers with slower dissociation rates. Eluted aptamers were 
concentrated and later desalted (during the fourth selection attempt) on a Vivaspin 500 5 
kDa MWCO centrifugal concentrator (Sartorius Stedim Biotech, Bohemia, NY). fGmH 
RNA recovered from a selection round was prepared for reverse transcription by 
annealing to 2 µM PDAC-3P (Lib 40) or PD1-Rev (Lib35) reverse primer by heating at 
70 °C for 10 min and immediately cooling on ice for 5 min. After 2 min at 42 °C, reverse 
transcription occurred upon addition of 10 U/µL SuperScript II Reverse Transcriptase 
(Life Technologies, Grand Island, NY), in a buffer containing 50 mM Tris-HCl, pH 8.3, 
0.5 mM dNTPs, 75 mM KCl, 3 mM MgCl2, and 10 mM DTT. cDNA products were 
amplified by PCR as described above for an optimized number of cycles. Sequencing of 
aptamer pools was performed via ligation into pJET1.2/blunt cloning vector (Thermo 
Scientific, Waltham, MA), transformation into DH5α E.coli cells, and high throughput 
sequencing (Eton Bioscience, Durham, NC). Dominant sequences, representing primary 
sequence groups, were selected for in vitro transcription and characterization. The 
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secondary structures of sequences of interest were predicted by the online program 
Mfold.  
3.4.2  Binding Analysis Using Biolayer Interferometry (BLI) and 5’ 32P Radioactive 
End-labeling 
Aptamer affinity for PD1, PDL1, or PDL2 was measured by using an Octet QK 
(Pall FortéBio, Menlo Park, CA) or via 5’ 32P Radioactive End-labeling. All assays were 
performed at room temperature. The Octet QK is a relatively new, label-free method 
based on BLI technology that measures molecular interactions via fiber optic biosensors 
(138). Due to its higher throughput, greater automation, and lower cost compared to other 
methods of affinity detection, BLI has been applied in the study of more and more 
molecular interactions (139-141). BLI assays were run at 30 °C on an Octet QK using 
either NTA or AHQ biosensors (Pall ForteBio Corp., Menlo Park, CA) and black 96-well 
microplates. All aptamer samples were prepared in selection buffer and applied to a 96-
well microplate in column arrangement. Aptamers and aptamer pools were assayed at 1 
µM.  
5’ 32P Radioactive End-labeling was performed on 50 pmol of input RNA in a 
reaction volume of 50 µL. RNA was desphosphorylated with 2.5 units Antarctic 
Phosphatase (New England Biolabs, Ipswich, MA) in 50 mM Bis-Tris-Propane-HCl, 1 
mM MgCl2, 0.1 mM ZnCl2 at pH 6 for 1.5 h. at 37 °C. Antarctic Phosphatase was 
inactivated via incubation at 65 °C for 5 minutes. The reaction was diluted to 500 µL 
with DEPC-treated ddH2O and concentrated to 50 µL on a Vivaspin 500 5 kDa MWCO 
centrifugal concentrator (Sartorius Stedim Biotech, Bohemia, NY). The reaction was 
again diluted and concentrated two additional times. Retentate volume was reduced 
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further to ≤ 19.5 µL using a Centrivap Concentrator (Labconco Corporation, Kansas City, 
MO). Retentate was then labeled in a total volume of 25 µL with 20 units T4 
Polynucleotide Kinase (New England Biolabs, Ipswich, MA) in 70 mM Tris-HCl, 10 mM 
MgCl2, 5 mM DTT, 10 µCi γ-32P-ATP at pH 7.6 for 1.5 h. at 37 °C. T4 Polynucleotide 
Kinase was inactivated via addition of 0.5 M EDTA, pH 8.0 to a final concentration of 31 
mM. Quick Spin Columns (G-50 Sephadex for Radiolabeled RNA Purification; Roche 
Diagnostics Corporation, Indianopolis, IN) removed excess γ-32P-ATP from the reaction 
via centrifugation at 1100 xg.  
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